

Drug Formulary

To search this document, right-click your mouse and select find, then type the generic drug name into the “find” box and press enter.

Index

Click the link to jump to the selected chapter

[Chapter 1 – Gastro-intestinal system](#)

[Chapter 2 – Cardiovascular system](#)

[Chapter 3 – Respiratory system](#)

[Chapter 4 – Central nervous system](#)

[Chapter 5 – Infections](#)

[Chapter 6 – Endocrine system](#)

[Chapter 7 – Obstetrics, gynaecology, and urinary tract disorders](#)

[Chapter 8 – Malignant disease and immunosuppression](#)

[Chapter 9 – Nutrition and blood](#)

[Chapter 10 – Musculoskeletal and joint diseases](#)

[Chapter 11 – Eye](#)

[Chapter 12 – Ear, nose, and oropharynx](#)

[Chapter 13 – Skin](#)

[Chapter 14 – Immunological products and vaccines](#)

[Chapter 15 – Anaesthesia](#)

[Emergency treatment of poisoning](#)

[Miscellaneous preparations](#)

Chapter 1

Gastro-intestinal system

1 **Gastro-intestinal system**

1.1 **Dyspepsia and gastro-oesophageal reflux disease**

1.1.1 **Antacids and simeticone**

Magnesium trisilicate

Suspension	5% (6 mmol Na ⁺ /10 mL)
Tablets, Compound, BP	Magnesium trisilicate 250 mg Aluminium hydroxide 120 mg

Activated Dimethicone

Infacol[®]

Paediatric use only

Liquid (Sugar free)	40 mg/mL (low Na ⁺)
------------------------	---------------------------------

1.1.2 **Compound alginates and proprietary indigestion preparations**

Compound alginic acid preparations

Sodium Bicarbonate, sodium alginate and calcium carbonate

Liquid (Sugar free)	Sodium alginate 250 mg, Sodium bicarbonate 133.5 mg, Calcium carbonate 80 mg/5mL (3 mmol Na ⁺ /5 mL)
------------------------	--

Gaviscon[®]

Infant Oral powder (Sugar free)	Sodium alginate 225 mg, Magnesium alginate 87.5 mg per dose (≡ half dual-sachet) (0.92 mmol Na ⁺ / dose)
------------------------------------	--

1.2 **Antispasmodics and other drugs altering gut motility**

Antimuscarinics

Atropine

Tablets	600 microgram
---------	---------------

Dicycloverine hydrochloride/ Dicyclomine hydrochloride

Tablets	10 mg, 20 mg
Syrup	10 mg in 5mL

Hyoscine butylbromide

Tablets	10 mg
Injection	20 mg/mL (1 mL ampoule)

Barnet and Chase Farm hospitals

Other antispasmodics

Mebeverine hydrochloride

Tablets	135 mg
Liquid	50 mg in 5mL
(Sugar free)	

Peppermint oil

Enteric coated capsules	0.2 mL per capsule
(Mintec[®])	

Peppermint water (BP 1973)

Peppermint Water (BP 1973) constitutes a 1 in 40 dilution of Concentrated Peppermint Water (BP 1973). The concentrated Peppermint Water (which is 40 times as strong as Peppermint Water BP 1973) should never be given undiluted

Motility stimulants

<u>Metoclopramide</u>	see section 4.6
<u>Domperidone</u>	see section 4.6

1.3

Antisecretory drugs and mucosal protectants

Helicobacter pylori infection

Studies have recommended the efficacy of one-week eradication regimens that include a proton pump inhibitor and clarithromycin with either metronidazole or amoxicillin. Treatment failure may reflect poor compliance, metronidazole resistance, or less commonly, clarithromycin resistance. If clarithromycin cannot be used, both amoxicillin and metronidazole need to be used instead.

See Trust antibiotic guidelines for most up to date H. pylori eradication regime(s)

Test for Helicobacter pylori

13C-urea (Helicobacter Test INFAI[®])

Oral powder	75 mg
(For dissolving in water)	

1.3.1

H₂-receptor antagonists

Ranitidine

Tablets	75 mg, 150 mg, 300mg
Effervescent tablets	150 mg
Syrup (sugar free)	75 mg in 5mL
Injection	25 mg in 1mL

1.3.3

Chelates and complexes

Tripotassium dicitratobismuthate

Tablets	120 mg
---------	--------

Sucralfate

Tablets	1 g
Suspension	1 g in 5mL

Barnet and Chase Farm hospitals

1.3.4 Prostaglandin analogues

Misoprostol

Tablets 200 microgram

*Approved for 3rd line treatment of massive obstetric haemorrhage due to uterine atony
(Unlicensed indication)*

1.3.5 Proton pump inhibitors

See Trust Proton Pump Inhibitor policy for latest guidance on PPI prescribing

Esomeprazole

(For grade C&D oesophagitis and treatment failures on current PPIs, according to guidelines)

Tablets 40mg

Capsules 40mg

Injections 40mg

Omeprazole

Capsules 10mg, 20mg

Dispersible tablets 10mg, 20mg, 40mg

(Restricted for paediatric use only)

Infusion 40mg

Lansoprazole

Capsules 15mg, 30mg

Orodispersible tablets 15mg, 30mg

1.4 Acute diarrhoea

1.4.1 Adsorbents and bulk-forming drugs

Kaolin BP

Mixture

1.4.2 Antimotility drugs

Codeine phosphate

Tablets See section 4.7.2

Co-Phenotrope

Tablets Co-phenotrope 2.5/0.025 (diphenoxylate hydrochloride 2.5 mg, atropine sulphate 25 micrograms)

Loperamide

Capsules 2 mg

Syrup 1 mg in 5 mL

(Sugar free)

Barnet and Chase Farm hospitals

1.5 Drugs used in inflammatory bowel disease

1.5.1 Aminosalicylates

Sulfasalazine

Tablets	500 mg
Enteric coated tablets	500 mg
Suspension	250 mg/5mL
Suppositories	500 mg

Mesalazine

Enteric-coated tablets (Asacol MR[®])	400 mg, 800 mg
Enteric-coated tablets (Salofalk[®])	250 mg, 500 mg
Modified-release tablets (Octasa MR[®])	400 mg, 800 mg
Modified-release tablets (Mesavant XL[®])	1.2 g
Modified-release tablets (Pentasa MR[®])	500 mg, 1 g
Modified-release Granules (Pentasa MR[®])	1 g, 2 g
Modified-release Granules (Salofalk[®])	1 g, 1.5 g
Suppositories	250 mg, 500 mg, 1g
Foam enema (Salofalk/Asacol[®])	1 g/metered application (14 doses)
Retention enema (Pentasa[®])	1g in 100 mL

Osalazine

Capsules	250 mg
----------	--------

1.5.2 Corticosteroids

Hydrocortisone

Foam in aerosol pack (Colifoam[®])	125 mg/application
---	--------------------

Prednisolone

Oral preparations	see section 6.3.2
Retention enema (Predsol[®])	20 mg in 100 mL
Foam in aerosol pack (Predfoam[®])	20 mg/metered application
Suppositories	5 mg

Budesonide

CR Capsules (Entocort[®])	3 mg
Capsules (Budenofalk[®])	3 mg

Barnet and Chase Farm hospitals

1.5.3 Drugs affecting the immune response

Cytokine modulators

Adalimumab

Prefilled pen 40 mg

Adalimumab - In accordance with NICE guidance

NICE unable to recommend for Ulcerative Colitis (moderate to severe, second line) due to lack of evidence submission (TA262)

Infliximab

Injection 100mg

Infliximab - In accordance with NICE guidance TA163 & TA187

1.6

Laxatives

1.6.1

Bulk-forming laxatives

Ispaghula husk

(Sugar and gluten free) 3.5 g/sachet

Methylcellulose

Tablets 500 mg

1.6.2

Stimulant laxatives

Bisacodyl

Enteric-coated tablets 5 mg

Suppositories 10 mg

Paediatric suppositories 5 mg

Dantron (dantron)

The indication for dantron is limited to use only for constipation in terminally ill patients of all ages.

With poloxamer '188' (as co-danthramer)

Capsules 25/200 (dantron 25mg, poloxamer 200mg)

Suspension 25/200 in 5mL (dantron 25mg, poloxamer 200 mg/5mL)

Strong capsules 37.5/500 (dantron 37.5mg, poloxamer 500mg)

Strong suspension 75/1000 in 5mL (dantron 75mg, poloxamer 1 g/5mL)

With docusate sodium (as co-danthrusate)

Capsules 50/60 (dantron 50mg, docusate sodium 60mg)

Suspension 50/60 in 5mL (dantron 50mg, docusate sodium 60 mg/5mL)

Barnet and Chase Farm hospitals

Docusate

Capsules	100 mg
Paediatric oral solution (Sugar free)	12.5 mg in 5 mL
Adult oral solution (Sugar free)	50 mg in 5mL
Micro-enema	120mg in 10g

Glycerol

Suppositories	1 g, 2 g, 4 g
---------------	---------------

Senna

Tablets	7.5 mg
Syrup	7.5 mg in 5 mL
Granules	

Sodium picosulphate

Elixir	5 mg in 5 mL
--------	--------------

1.6.3

Faecal softeners

Arachis (peanut) oil

Enema	130 mL
-------	--------

Liquid Paraffin BP

Liquid

1.6.4

Osmotic laxatives

Lactulose

Solution	3.1-3.7 g in 5mL
----------	------------------

Macrogol oral powder

Oral powder	macrogol "3350"
-------------	-----------------

Movicol[®] liquid

Liquid	macrogol "3350"
--------	-----------------

Movicol[®] Paediatric

Oral powder	macrogol "3350"
-------------	-----------------

(Restricted for treatment of faecal impaction in children. Not to be used routinely for the chronic treatment of constipation)

Magnesium hydroxide

Mixture, BP	Aqueous suspension containing about 8% Hydrated magnesium oxide
-------------	---

Phosphates (Fletchers' Phosphate Enema[®])

Enema	128 mL
-------	--------

Sodium citrate (Relaxit Micro-enema[®])

Enema	450 mg
-------	--------

Barnet and Chase Farm hospitals

1.6.5

Bowel cleansing solutions

Citramag[®] (Magnesium citrate)

Fleet Phospho-soda[®] (Phosphates)

This preparation is not licensed for use in children.

Klean-Prep[®] (Macrogols)

Note: Contraindicated in patients under 20 kg body-weight; allergic reactions reported. This preparation is not licensed for use in children.

Moviprep[®] (Macrogols)

This preparation is approved for In-patients use and also for Out-patients who are at risk of developing renal impairment and electrolyte imbalance with Picolax.

Picolax[®] (Sodium picosulfate with magnesium citrate)

This preparation can be used in children over 1 year.

Note: Low residue diet recommended for 2 days before procedure and copious intake of water or other clear fluids recommended during treatment.

1.6.6

5HT₄-receptor agonists

Prucalopride (Resolor)[®]

Tablets 1 mg, 2 mg

In accordance with NICE guidance TA 211

Restricted to prescribing by gastroenterologists and consultant geriatricians only. Registration form must be completed and submitted with prescription for pharmacy to supply.

1.7

Local preparations for anal and rectal disorders

1.7.1

Soothing haemorrhoidal preparations

Anusol[®]

Cream 23 g pack size

Suppositories

1.7.2

Compound haemorrhoidal preparations with corticosteroids

Anusol-HC[®]

Ointment 30 g pack size

Suppositories

Proctofoam HC[®]

Foam enema

Proctosedyl[®]

Ointment 30 g pack size

Suppositories

Scheriproct[®]

Suppositories

Xyloproct[®]

Ointment 30 g pack size

Barnet and Chase Farm hospitals

1.7.3	<u>Rectal sclerosants</u>	
	<u>Oily Phenol</u>	
	Injection, BP	5% (2 mL, 5 mL amp)
1.7.4	<u>Management of anal fissures</u>	
	<u>Glyceryl Trinitrate</u>	
	Rectal ointment	0.4%
	(Rectogesic[®])	
	<i>For the treatment of anal fissures</i>	
1.9	<u>Drugs affecting intestinal secretions</u>	
1.9.1	<u>Drugs affecting biliary composition and flow</u>	
	<u>Ursodeoxycholic acid</u>	
	Tablets	150 mg
	Capsules	250 mg
	Suspension	250 mg in 5mL
	(Sugar free)	
1.9.2	<u>Bile acid sequestrants</u>	
	<u>Colestyramine (Cholestyramine)</u>	
	Powder	4 g per sachet
1.9.4	<u>Pancreatin</u>	
	Capsules	protease 600 units, lipase 10 000 units, amylase 8000 units
	(Creon 10000[®])	
	Capsules	protease 1000 units, lipase 25 000 units, amylase 18 000 units
	(Creon 25000[®])	
	Capsules	protease 1600 units, lipase 40 000 units, amylase 25 000 units
	(Creon 40000[®])	
	Gastro resistant granules	protease 200 units, lipase 5 000 units, amylase 3600 units
	(Creon Micro[®])	

Chapter 2
Cardiovascular System

2 Cardiovascular system

2.1 Positive inotropic drugs

2.1.1 Cardiac glycosides

Digoxin

Tablets	62.5 micrograms, 125 micrograms, 250 micrograms
Elixir	50 micrograms in 1 mL
Injection	100 micrograms in 1mL, 500 micrograms in 2mL

Digitoxin

Tablets	100 micrograms
---------	----------------

Digoxin specific antibody

Injection (DigiFab [®])	40mg
-----------------------------------	------

2.2 Diuretics

2.2.1 Thiazides and related diuretics

Bendroflumethiazide

Tablets	2.5 mg, 5 mg
---------	--------------

Chlortalidone (Chlorthalidone)

Tablets	50mg
---------	------

Cyclopenthiiazide

Tablets	500 micrograms
---------	----------------

Indapamide

Tablets	2.5 mg
Slow release tablets	1.5 mg

Metolazone

Tablets	5 mg
---------	------

2.2.2 Loop diuretics

Furosemide

Tablets	20 mg, 40 mg, 500 mg
Oral solution (Sugar free)	40 mg in 5mL, 50mg in 5mL
Paediatric liquid (Sugar free)	1mg in 1mL
Injection	20 mg in 2mL, 50 mg in 5mL, 250 mg in 25mL

Barnet and Chase Farm hospitals

Bumetanide

Tablets	1 mg, 5 mg
Liquid (Sugar free)	1mg in 5mL
Injection	500 micrograms in 1mL (4mL amp)

2.2.3

Potassium-sparing diuretics and aldosterone antagonists

Amiloride

Tablets	5 mg
Oral solution	5 mg in 5mL

Aldosterone antagonists

Spironolactone

Tablets	25 mg, 100 mg
Oral suspension	50 mg in 5 mL

Eplerenone

Tablets	25 mg, 50 mg
---------	--------------

2nd line treatment of heart failure in patients intolerant to spironolactone, as per NICE guidance

2.2.4

Potassium-sparing diuretics with other diuretics

Co-amilozide (Amiloride hydrochloride, Hydrochlorothiazide)

Tablets	2.5/25, 5/50
---------	--------------

Co-triamterzide (Triamterne, Hydrochlorothiazide)

Tablets	50/25
---------	-------

Co-amilofruse (Amiloride, Furosemide)

Tablets	2.5/20, 5/40
---------	--------------

2.2.5

Osmotic diuretics

Mannitol

Infusion	10%, 20%
----------	----------

2.2.7

Carbonic anhydrase inhibitors

see section 11.6

2.3 Anti-arrhythmic drugs

2.3.2 Drugs for arrhythmias

Adenosine

Injection	6 mg in 2mL
Intravenous infusion (Adenoscan [®])	30mg in 10mL

Amiodarone hydrochloride

Tablets	100 mg, 200 mg
Injection	150 mg in 3mL
Pre-filled syringe	300mg in 10mL

Barnet and Chase Farm hospitals

Disopyramide

Capsules	100 mg, 150mg
Modified release tablets	250 mg
Injection	50 mg in 5mL

Dronedarone

Tablets	400mg
---------	-------

Approved for use in secondary care. To be prescribed as per NICE guidance.

Flecainide acetate

Tablets	50 mg, 100mg
Injection	150 mg in 15mL

Propafenone

Tablets	150 mg
---------	--------

Lidocaine (Lignocaine) hydrochloride

Injection	1% (2 mL, 5 mL, 10 mL, 20 mL)
Injection	2% (2 mL, 5 mL, 20 mL)
Infusion 0.2%	2 mg/mL in glucose 5% (500-mL)
Min-I-Jet Injection 2%	20 mg/mL (5 mL syringe)

2.4

Beta-adrenoceptor blocking drugs

Propranolol hydrochloride

Tablets	10 mg, 40 mg, 80 mg, 160mg
Modified release capsules	80 mg, 160 mg
Liquid (sugar-free)	5mg in 5mL, 10mg in 10mL
Injection	1mg in 1mL

Acebutolol

Capsules	100mg, 200mg
Tablets	400mg

Atenolol

Tablets	25 mg, 50 mg, 100 mg
Syrup	25 mg in 5 mL
(Sugar free)	

Atenolol with diuretic

Co-tenidone (atenolol, chlortalidone)

Tablets	50/12.5, 100/25
---------	-----------------

Barnet and Chase Farm hospitals

Bisoprolol

For use in stable moderate to severe heart failure, as an adjunct to treatment with an ACE inhibitor, a diuretic and possibly a cardiac glycoside. Beta-blocker treatment should be started under specialist supervision at a very low dose and titrated very slowly over a period of weeks or months.

Tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg,
7.5 mg, 10 mg

Esmolol

Injection 2.5 g in 10 mL, 100mg in 10mL

(For Consultant Cardiologists only)

Labetalol

(For use in obstetrics only)

Tablets 100 mg, 200mg

Injection 100 mg in 20 mL

Metoprolol tartrate

Tablets 50 mg, 100mg

Injection 1mg in 1mL

Nebivolol

Tablets 5 mg

2nd line treatment for patients intolerant or failed bisoprolol/metoprolol for heart failure patients with concurrent PCD/COPD

Oxprenolol

Modified- release tablets 160mg

Sotalol hydrochloride

Tablets 40 mg, 80 mg

Timolol

Tablets 10mg

2.5 Hypertension and heart failure

2.5.1 Vasodilator antihypertensive drugs

Bosentan

Tablets 62.5mg

Diazoxide

Injection 300mg in 20mL

Hydralazine hydrochloride

Tablets 25 mg, 50mg

Injection 20 mg in 1 mL

Minoxidil

Tablets 2.5mg, 10mg

Sildenafil (Revatio®)

Tablets 20mg

Barnet and Chase Farm hospitals

2.5.2

Centrally acting antihypertensives

Clonidine hydrochloride

Tablets	100 micrograms
Injection	See section 4.7.4

Methyldopa

(For use in obstetrics)

Tablets	125 mg, 250 mg, 500mg
---------	-----------------------

2.5.3

Adrenergic neurone blocking drugs

Guanethidine

Injections	10mg in 1mL
------------	-------------

2.5.4

Alpha-adrenoceptor blocking drugs

Doxazosin

Tablets	1 mg, 2 mg, 4 mg
---------	------------------

Prazosin

Tablets	500 micrograms, 1 mg
---------	----------------------

Phenoxybenzamine

Capsules	10 mg
----------	-------

Phentolamine

Injection	10 mg in 1mL
-----------	--------------

2.5.5 Drugs affecting the renin-angiotensin system

2.5.5.1

Angiotensin-converting enzyme inhibitors

Captopril

Tablets	12.5 mg, 25 mg, 50mg
---------	----------------------

Enalapril

Tablets	2.5 mg, 5 mg, 10 mg, 20 mg
---------	----------------------------

Lisinopril

Tablets	2.5 mg, 5 mg, 10 mg, 20 mg
---------	----------------------------

Perindopril

Tablets	2 mg, 4 mg, 8mg
---------	-----------------

Ramipril

Capsules	1.25 mg, 2.5 mg, 5 mg, 10 mg, titration pack
----------	--

Barnet and Chase Farm hospitals

2.5.5.2 Angiotensin-II receptor antagonists (AR2A)

Candesartan

Tablets 2 mg, 4 mg, 8 mg, 16mg, 32mg

Irbesartan

For the treatment of renal disease in patients with hypertension and Type 2 diabetes

Tablets 75 mg, 150 mg, 300 mg

Losartan

1st line treatment where an AR2A is appropriate, because of its cost effectiveness

Tablets 25 mg, 50 mg, 100 mg

Valsartan

Approved form of treatment if MI in patients intolerant of ACE inhibitors

Capsules 40mg, 80mg, 160mg

Tablets 40mg

2.6 Nitrates, Calcium-channel blockers, and other antianginal drugs

2.6.1 Nitrates

Glyceryl trinitrate

Sublingual tablets 500 micrograms

Sublingual aerosol spray 400 micrograms per metered dose

Injection 5mg in 5mL

Patches 5 mg/ 24 hours, 10 mg/ 24 hours

Isosorbide dinitrate

Tablets 10 mg, 20 mg

Modified release tablets 20 mg

Injection 500 micrograms in 1mL (0.05%),
1 mg in 1 mL (0.1%)

Isosorbide mononitrate

Tablets 10 mg, 20 mg, 40mg

Modified release tablets 60mg

Trimetazidine

Tablets 20mg

Unlicensed indication approved for the treatment of intractable angina. Restricted to consultant cardiologists only.

2.6.2 Calcium-channel blockers

Amlodipine

Tablets 5 mg, 10 mg

Barnet and Chase Farm hospitals

Diltiazem

Standard formulation

Note: This formulation has been licensed as a generic and there is no requirement for brand name dispensing. The duration of action corresponds to three times daily administration.

Tablets, m/r 60 mg

Longer acting formulations

Note: Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of diltiazem, prescribers should specify the brand to be dispensed.

Tablets	90 mg, 120 mg
(Tildiem Retard [®])	
Capsules	
(Tildiem LA [®])	200 mg, 300 mg
(Slozem [®])	120mg, 180mg, 240mg, 300mg

Nifedipine

Standard formulations

Capsules 5 mg, 10 mg

Modified release formulations

Note: Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of nifedipine, prescribers should specify the brand to be dispensed. Modified-release formulations may not be suitable for dose titration in hepatic disease.

Capsules	10 mg, 20 mg
(Coracten SR [®])	
Capsules	30 mg, 60 mg
(Coracten XL [®])	

Nimodipine

(For prevention and treatment of ischaemic neurological deficits following subarachnoid haemorrhage)

Tablets	30 mg
Intravenous infusion	10 mg in 50 mL

Verapamil hydrochloride

Tablets	40 mg, 80 mg, 120 mg
Injection	5 mg in 2 mL
Modified release tablets	120 mg, 240 mg, 240mg
Modified release capsules	120 mg, 180 mg, 240 mg
Liquid	40mg in 5mL

Barnet and Chase Farm hospitals

Other antianginal drugs

Ivabradine

As per NICE and local guidelines

Tablets 5mg

Ivabradine - In accordance with NICE guidance
Ivabradine is recommended as an option for treating chronic heart failure for some groups of patients (TA267)

Nicorandil

Tablets 10 mg, 20 mg

Ranolazine

Modified-release tablets 375mg, 500mg

Approved for Cardiology consultant initiation only

2.6.3

Peripheral vasodilators and related drugs

Naftidrofuryl oxalate

Capsules 100 mg

Naftidrofuryl oxalate - In accordance with NICE guidance
A recommended option for intermittent claudication in peripheral arterial disease (TA223)

Inositol

Tablets 500mg

Inositol - In accordance with NICE guidance
Not recommended for intermittent claudication in peripheral arterial disease (TA223)

Oxerutins

Capsules 250mg

2.7 Sympathomimetics

2.7.1 Inotropic sympathomimetics

Dobutamine

Strong sterile solution 250 mg in 20 mL

(For dilution and use as an intravenous infusion)

Dopamine hydrochloride

Sterile concentrate 200 mg in 5 mL, 800 mg in 5 mL

(For dilution and use as an intravenous infusion)

Isoprenaline

Injection 2.25mg in 2mL

Barnet and Chase Farm hospitals

2.7.2

Vasoconstrictor sympathomimetics

Ephedrine hydrochloride

Injection 30 mg in 10 mL (ampoule or pre-filled syringe)

Metaraminol

(For use in obstetrics only)

Injection 10 mg in 1 mL

Noradrenaline acid tartrate/ Norepinephrine bitartrate

Injection 2 mg/ mL, equivalent to noradrenaline base
1 mg/ mL (2mL and 4 mL ampoules)

Phenylephrine

Injection 10mg in 1mL

2.7.3

Cardiopulmonary resuscitation

Adrenaline/ Epinephrine

Injection 1 in 10 000 100 micrograms/ mL (10 mL ampoule or pre-filled syringe)

2.8

Anticoagulants and protamine

2.8.1

Parenteral anticoagulants

Standard or unfractionated heparin

Heparin calcium

Injection 5000 units in 0.2 mL syringe

Heparin sodium

Injection 1000 units in 1 mL, 5000 units in 0.2 mL
5000 units in 1 mL, 5000 units in 5mL
25 000 units in 1 mL, 25 000 units in 5 mL
Infusion 500 units (500mL bag)

Low molecular weight heparins (LMWH)

Tinzaparin (Innohep) – non-formulary.
Rejected by North Central London JFC, as the risk of additional LMWH on formulary outweighed any benefits.

Fondaparinux

*Low molecular weight heparin of choice for ACS treatment as per NICE guidance
“CG92 Venous thromboembolism: reducing the risk “*

Prefilled syringe 2.5 mg in 0.5 mL, 7.5mg in 0.6mL
100 mg, 120 mg, 150mg

Barnet and Chase Farm hospitals

Enoxaparin

Injection 20 mg, 40 mg, 60 mg, 80 mg, 100mg, 120mg, 150mg

Epoprostenol

Infusion 500-microgram vial (with diluent)

Bivalirudin - In accordance with NICE guidance
Recommended as a possible treatment for adults with STEMI having percutaneous coronary intervention (TA230)

Heparin flushes

To maintain patency of catheters, cannulas, etc.

Solution 100 units/ mL (2mL ampoule)

200 units flushed through every 4-8 hours or as required. Not for therapeutic use.

Solution 10 units/mL (5 mL ampoule)

50 units flushed through every 4 hours or as required.

(For maintaining patency of peripheral venous catheters, sodium chloride injection 0.9% is as effective as heparin flushes)

2.8.2

Oral anticoagulants

Warfarin sodium

Tablets 0.5mg, 1 mg, 3 mg

Liquid 5mg in 5mL

Acenocoumarol/ Nicoumalone

(For use in existing patients only)

Tablets 1 mg

Phenindione

Tablets 10 mg, 25 mg, 50mg

Dabigatran

Capsules 75mg, 110mg

Dabigatran - In accordance with NICE guidance and in line with local treatment pathway
A recommended option for atrial fibrillation patients with risk factors to prevent stroke and embolism. (TA249)

Rivaroxaban

Tablets 15mg, 20mg

Rivaroxaban - In accordance with NICE guidance and in line with local treatment pathway
Recommended as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with non-valvular atrial fibrillation with 1 or more risk factors (TA275)
A recommended option for stroke prevention for atrial fibrillation patients with risk factors (TA256)

Barnet and Chase Farm hospitals

A recommended option for treating DVT, and to help prevent a pulmonary embolism or another DVT (TA261)

Recommended as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with non-valvular atrial fibrillation with 1 or more risk factors (TA275)

Rivaroxaban is recommended as an option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism in adults. (TA287)

Apixaban - In accordance with NICE guidance and in line with local treatment pathway

2.8.3 Protamine sulphate

Protamine sulphate

Injection 50 mg in 5 mL

2.9

Antiplatelet drugs

Aspirin

Tablets 75 mg

Enteric coated tablets 75mg

Clopidogrel

Tablets 75 mg

Dipyridamole

Tablets 25mg, 100 mg

Modified release capsules 200 mg

Injection 10mg in 2mL

Dipyridamole with aspirin

Modified release capsules 200 mg / 25 mg

(Asasantin Retard[®])

Prasugrel

Tablets 5 mg, 10 mg

As per NICE and local guidelines

Ticagrelor

Tablets 90mg

Ticagrelor - In accordance with NICE guidance
Recommended combined with low-dose aspirin for up to a year for specified people with acute coronary syndromes (TA236)

Ticlopidine

Tablets 250mg

Barnet and Chase Farm hospitals

Tirofiban

(For use in CCU only)

Concentrate for 12.5 mg in 50 mL

Intravenous infusion

2.10.2

Fibrinolytic drugs

Alteplase (rt-PA tissue-type plasminogen activator)

Injection 20mg, 50 mg

Alteplase - In accordance with NICE guidance
 A recommended option within 4.5 hours of an acute ischemic stroke if imaging shows no haemorrhage (TA264)

Retepase

Injection 10 units/vial

As per NICE guidance

Streptokinase

Injection 250 000 unit vial, 750 000 unit vial,
 1.5 million unit vial

Urokinase

Injection 10 000 unit vial

2.11

Antifibrinolytic drugs and haemostatics

Aprotinin

Injection 10 000 kallikrein inactivator units/ mL (50mL)

Tranexamic acid

Tablets 500 mg

Injection 500 mg in 5 mL

Human Prothrombin Complex (Octaplex[®])

Injection 500 IU powder for injection

Approved for use by consultant haematologists only, as per protocol

Drotrecogin Alfa (Xigris[®])

Injection 5mg, 20mg

Factor VIIa Recombinant (NovoSeven[®])

Injection 1mg, 2mg, 5mg

For consultant use only for intractable bleeding in accordance with protocols

Barnet and Chase Farm hospitals

2.12

Lipid-regulating drugs

Statins

For Primary and Secondary prevention of Coronary Heart Disease - Simvastatin and Pravastatin.

For primary hypercholesterolaemia, combined (mixed) hyperlipidaemia in patients who have not responded to diet and other appropriate measures – Simvastatin and atorvastatin

Atorvastatin

Tablets 40 mg, 80 mg

May 2010 - Please note atorvastatin 10mg and 20mg strengths are no longer on the Trust formulary. Patients admitted with those strengths will be switched to simvastatin 40mg according to guideline.

Pravastatin

Tablets 10 mg, 20 mg, 40 mg

Rosuvastatin

Tablets 5 mg, 10 mg, 20 mg, 40mg

(In line with NICE guidance)

Simvastatin

Tablets 10 mg, 20 mg, 40 mg

Bile acid sequestrants

Colestyramine

Powder (sugar-free) 4 g / sachet

Colestipol

Granules 5g / sachets

Ezetimibe

Tablets 10mg

Approved in line with NICE TA132. To be used when all statins tried and failed.

Fibrates

Bezafibrate

Tablets 200 mg

Modified release tablets 400 mg

Omega-3 fatty acid compounds

Omacor[®]

Capsules 1g

Maxepa[®]

Capsules 1g

Barnet and Chase Farm hospitals

2.13

Local sclerosants

Ethanolamine Oleate

Injection 5%

Sodium tetradecyl sulphate

Injection 0.2% (5 mL ampoule), 0.5% (2mL ampoule),
1% (2 mL ampoule), 3% (2 mL ampoule)

Chapter 3

Respiratory System

3 Respiratory system

3.1 Bronchodilators

3.1.1 Adrenoceptor agonists

3.1.1.1 Selective beta-2 agonists

Salbutamol

Tablets	2mg, 4 mg
Modified release tablets	4 mg
Modified release capsules	4mg, 8mg
Oral solution	2 mg in 5 mL
Injection	500 micrograms in 1 mL
Infusion	1 mg in 1 mL
Inhaler (CFC free)	100 micrograms per puff
Nebuliser solution	2.5 mg in 2.5 mL, 5 mg in 2.5 mL

Terbutaline

Injection	500 micrograms in 1mL (1mL and 5mL amps)
Tablets	5mg
Liquid	1.5mg in 5mL
Nebules	5mg in 2mL

Longer-acting beta-2 adrenoceptor stimulants

Formoterol

Easyhaler	12 micrograms
Turbohaler	6 micrograms, 12 micrograms

Salmeterol

Inhaler	25 micrograms
Diskhaler	50 micrograms

The following products are **only** for patients unable to use standard metered dose inhalers (see flow diagram below):

Salbutamol

Accuhaler	200 micrograms
Autohaler	100 micrograms

(**Salamol Easi-breathe[®]**, **Airomir[®]**, **Clickhaler[®]**)

Terbutaline

Turbohaler	500 micrograms
------------	----------------

Salmeterol

Accuhaler	50 micrograms
-----------	---------------


Note: Inhaler = metered dose inhaler
Turbohaler, Accuhaler = dry powder inhaler
Autohaler = breath-actuated inhaler

Barnet and Chase Farm hospitals

3.1.1.2	Other adrenoceptor agonists	
	<u>Adrenaline (epinephrine)</u>	See section 3.4.3
	<u>Ephedrine</u>	
	Tablets	15mg, 30mg
	<u>Orciprenaline</u>	
	Liquid	10mg in 5mL
3.1.2	Antimuscarinic bronchodilators	
	<u>Ipratropium bromide</u>	
	Inhaler	20 micrograms
	Nebuliser solution	250 micrograms in 1mL, 500 micrograms in 2mL
	<u>Tiotropium</u>	
	Inhaler	18 micrograms
	(Spiriva [®] HandiHaler [®])	
	Solution for inhalation	2.5 micrograms
	(Spiriva [®] Respimat [®])	
3.1.3	Theophylline	
	<i>Modified release presentations of theophylline and its salts should always be prescribed and dispensed by brand.</i>	
	<u>Theophylline</u>	
	Modified release capsules	60 mg, 125 mg, 250 mg
	(Slo-Phyllin [®])	
	Modified release tablets	
	(Uniphyllin Continus [®])	200 mg, 300 mg, 400 mg
	(Nuelin SA [®])	175mg, 250mg
	<u>Aminophylline</u>	
	Modified release tablets	225 mg, 350 mg
	(Phyllocontin Continus [®])	
	Injection	250 mg in 10 mL
3.1.5	Drug delivery devices	
	Babyhaler [®]	
	Haleraid [®]	
	Volumatic [®] and Paediatric Volumatic [®]	
	AeroChamber [®] (yellow, orange and blue)	
	Sodium chloride 0.9% 2.5mL nebuliser diluent	
	Peak flow meters Mini-Wright [®] (outpatients and TTA's only)	

Barnet and Chase Farm hospitals

The choice of drug delivery device in **adults** should be governed by the following flow diagram:



Mannitol dry powder – In accordance with NICE guidance
Recommended as an option for treating cystic fibrosis in some patients
(TA266)

3.2 **Corticosteroids**

Beclometasone

Inhaler (CFC-free) 50 micrograms, 100 micrograms,
(Clenil Modulite[®]) 200 micrograms, 250 micrograms

Breath-actuated 50 micrograms, 100 micrograms,
(Qvar[®] Easi-Breathe[®])

Fostair[®] 100 micrograms beclometasone, 6 micrograms formoterol

As per BTS guidelines step 3

Budesonide

Inhaler 100 micrograms, 200 micrograms

Turbohaler 100 micrograms, 200 micrograms,
400 micrograms

Nebuliser suspension 500 micrograms in 2mL, 1mg in 2mL

Ciclesonide

Inhaler 80 micrograms, 160micrograms

For consultant use only in patients who are intolerant of other inhaler steroids in accordance with guidelines

Symbicort[®]

Turbohaler 100 micrograms budesonide, 6 micrograms formoterol
200 micrograms budesonide, 6 micrograms formoterol
400 micrograms budesonide, 12 micrograms formoterol

Barnet and Chase Farm hospitals

Fluticasone

Inhaler (CFC-free)	50 micrograms, 125 micrograms, 250 micrograms
Accuhaler	50 micrograms, 100 micrograms 250 micrograms, 500 micrograms
Diskhaler	50 micrograms, 250 micrograms
Nebules	500 micrograms in 2mL, 2mg in 2mL

Flutiform®

Inhaler	50 micrograms fluticasone, 5 micrograms formeterol 125 micrograms fluticasone, 5 micrograms salmeterol 250 micrograms fluticasone, 10 micrograms salmeterol
---------	---

Fluticasone/Formeterol (Flutiform) (for asthma)
Recommended for new patients requiring combination inhaled corticosteroid and long-acting beta-agonist therapy , by North Central London JFC

Seretide®

Inhaler	50 micrograms fluticasone, 25 micrograms salmeterol 100 micrograms fluticasone, 25 micrograms salmeterol 250 micrograms fluticasone, 25 micrograms salmeterol
Accuhaler	100 micrograms fluticasone, 50 micrograms salmeterol 250 micrograms fluticasone, 50 micrograms salmeterol 500 micrograms fluticasone, 50 micrograms salmeterol

3.3 Cromoglicate and related therapy, leukotriene receptor antagonists, and phosphodiesterase type-4 inhibitors

3.3.1 Cromoglicate and related therapy

Sodium cromoglicate

Inhaler	5mg
---------	-----

3.3.2 Leukotriene receptor antagonists

Montelukast

Tablets	10 mg
Paediatric tablets (Chewable)	4 mg, 5 mg
Granules	4mg

Roflumilast (restricted use) - In accordance with NICE guidance
Only recommended as part of a clinical trial (TA244)

Barnet and Chase Farm hospitals

3.4 Antihistamines, hyposensitisation, and allergic emergencies

3.4.1 Antihistamines

Non-sedating antihistamines

Cetirizine hydrochloride

Tablets	10 mg
Oral solution	5mg in 5 mL

Loratadine

Tablets	10 mg
Liquid	5mg in 5mL

Desloratadine

(Restricted to children age 1-2 years old)

Syrup	2.5 mg in 5 mL
-------	----------------

Levocetirizine –non-formulary. Not approved by BCFH D&T panel as further safety and efficacy data required.

Sedating antihistamines

Alimemazine Tartrate (Trimeprazine tartrate)

Tablets	10 mg
Syrup	7.5 mg in 5 mL
Syrup Forte	30 mg in 5 mL

Chlorphenamine maleate

Tablets	4 mg
Syrup	2 mg in 5 mL
Injection	10 mg in 1 mL

Cyproheptadine

Tablets	4mg
---------	-----

Hydroxyzine hydrochloride

Tablets	10 mg, 25 mg
Liquid	10mg in 5mL

Promethazine hydrochloride

Tablets	10 mg, 25 mg
Elixir	5 mg in 5 mL
Injection	25 mg in 1 mL

3.4.2 Allergen immunotherapy

Omalizumab

Injection	75mg in 0.5mL, 150mg in 1mL
-----------	-----------------------------

As per NICE guidance TA278

Bee and Wasp venom extract (Pharmalgan) - In accordance with NICE guidance Recommended treatment for bee or wasp venom allergy after a severe reaction, or moderate reaction in certain circumstance (TA246)

Barnet and Chase Farm hospitals

3.4.3 Allergic emergencies

Adrenaline (epinephrine)

Injection	1 in 1000 (1 mg in 1 mL)
	1 in 10 000 (100 micrograms in 1mL)

Epipen[®] 300 micrograms

Epipen Junior[®] 150 micrograms

C1-Esterase Inhibitor

Injection	500 units
-----------	-----------

3.5 Respiratory stimulants and pulmonary surfactants

3.5.1 Respiratory Stimulants

Doxapram

Injection	100 mg in 5 mL
Intravenous infusion	2 mg in 1 mL (in glucose 5%)

3.5.2 Pulmonary Surfactants

Poractant alfa

Suspension (Curosurf[®])	120 mg in 1.5 mL, 240 mg in 3 mL
---	----------------------------------

3.6 Oxygen

Oxygen prescribing

Oxygen, used to treat hypoxaemia, may cause respiratory depression. It should therefore be considered a drug and be prescribed by an authorised prescriber. An accurate prescription should include the flow rate, the concentration, the delivery device and the duration. Oxygen should not be administered on a 'prn' basis as a treatment for breathlessness.

Venturi Mask: These masks deliver a fixed concentration of oxygen irrespective of the patient's breathing pattern. The flow rate indicated on each valve is the **minimum** rate required to deliver the specified concentration. Flow should be adjusted to meet patient's inspiratory flow requirements. Increased flow DOES NOT alter the concentration or increase the chance of CO₂ retention, but reduces the work of breathing.

Nasal Cannulae: Best suited for chronic usage. Oxygen concentrations are dependent upon patient breathing pattern and flow rate. 2 litres by nasal Cannulae MAY deliver up to 40% O₂ in some people.

Monitoring Oxygenation:

Pulse oximetry is a non-invasive way of monitoring the percentage of haemoglobin that is saturated with O₂. It CANNOT measure CO₂ levels, and it requires good peripheral circulation.

Arterial blood gases (ABG) give a direct measurement of partial pressure of O₂ and CO₂, as well as the acid-base state. ABG's should be performed before oxygen therapy if possible. They should be repeated within 30-60 minutes after any change in O₂ therapy.

Acute oxygen therapy should be PRESCRIBED and REVIEWED DAILY. Details of concentration, route of administration and humidification should be given.

Recommended methods:

Either controlled oxygen (fixed percentage) via mask at 24, 28, 35, 40, 60%

Or uncontrolled oxygen via nasal cannulae at 1, 2 or possibly 4 L/minute

Barnet and Chase Farm hospitals

3.7 Mucolytics

Carbocisteine

Capsules 375mg
Oral liquid 250 mg in 5 mL

To be used in COPD patients to reduce exacerbations

Dornase Alfa

Nebules 2500 units in 2.5mL

Hypertonic sodium Chloride

Nebuliser solution 3%, 7%

3.8 Aromatic Inhalations

Benzoin compound

Tincture

Menthol & Eucalyptus

Inhalation

3.9 Cough preparations

3.9.1 Cough Suppressants

Codeine

Linctus (sugar-free) 5mg in 5mL

Methadone

Linctus 2mg in 5mL

Pholcodine

Linctus, BP (Sugar-free) 5 mg in 5 mL

3.9.2 Expectorant and demulcent cough preparations

Simple Linctus BP (sugar free)

Simple Linctus paediatric BP 3 mg in 5 mL

3.10 Systemic nasal decongestants

Pseudoephedrine

Tablets 60mg
Elixir 30 mg in 5 mL

3.11 Antifibrotics

Pirfenidone

Capsule 267mg

Pirfenidone (Esbriet) - In accordance with NICE guidance
A recommended option for treating idiopathic pulmonary fibrosis if the patient has a forced vital capacity between 50% and 80% predicted (TA282)

Chapter 4
Central Nervous System

4 Central nervous system

4.1 Hypnotics and anxiolytics

4.1.1 Hypnotics

Benzodiazepines

Flurazepam

Capsules 30mg

Nitrazepam

Tablets 5 mg

Oral suspension 2.5 mg in 5 mL

Temazepam

Tablets 10 mg, 20mg

Oral solution 10 mg in 5 mL

Zapelon

Capsules 5mg, 10mg

Zopiclone

Tablets 3.75mg, 7.5mg

Chloral and derivatives

Chloral hydrate

Oral solution 1mg in 5mL, 500 mg in 5 mL

Chloral Betaine (Welldorm[®])

Tablets 707mg (≅414mg chloral hydrate)

Liquid 143mg in 5mL

Clomethiazole (Chlormethiazole)

(For an equivalent therapeutic effect, 1 capsule ≅ 5 mL syrup)

Capsules 192 mg

Syrup 31.5mg in 1mL

4.1.2 Anxiolytics

Diazepam

Tablets 2 mg, 5 mg, 10 mg

Oral solution 2 mg in 5 mL

Injection 10 mg in 2 mL

Injection (emulsion) 10 mg in 2 mL

Rectal tubes (Rectal solution) 2.5 mg, 5 mg, 10 mg

Chlordiazepoxide

Capsules 5 mg, 10 mg

Lorazepam

Tablets 1 mg, 2.5mg

Injection 4 mg in 1 mL

Barnet and Chase Farm hospitals

	<u>Buspirone</u>	
	Tablets	5 mg, 10mg
4.2	Drugs used in psychoses and related disorders	
4.2.1	Antipsychotic drugs	
	<u>Benperidol</u>	
	Tablets	250 microgram
	<u>Chlorpromazine</u>	
	Tablets	25 mg, 50 mg, 100 mg
	Oral solution	25 mg in 5 mL, 100 mg in 5 mL
	Injection	50 mg in 2 mL
	<u>Flupentixol (flupentixol)</u>	
	Tablets	3 mg
	<u>Haloperidol</u>	
	Capsules	500 micrograms
	Tablets	1.5 mg, 5 mg, 10 mg
	Oral liquid (Sugar free)	5mg in 5mL, 10mg in 5mL
	Injection	5 mg in 1 mL
	<u>Levomepromazine (Methotrimeprazine)</u>	
	Tablets	25 mg
	Injection	25 mg in 1 mL
	<u>Pericyazine</u>	
	Tablets	2.5mg, 10mg
	<u>Perphenazine</u>	
	Tablets	2 mg, 4 mg
	<u>Pimozide</u>	
	Tablets	4 mg
	<u>Promazine hydrochloride</u>	
	Tablets	25 mg, 50 mg
	Suspension	25mg in 5mL, 50 mg in 5 mL
	<u>Sulpiride</u>	
	Tablets	200 mg, 400 mg
	Oral solution	200 mg in 5 mL
	<u>Trifluoperazine</u>	
	Tablets	1 mg, 5 mg
	Oral solution	1mg in 5mL, 5 mg in 5 mL
	<u>Zuclopenthixol acetate</u>	
	Injection	50 mg in 1 mL, 100mg in 2mL
	(Clopixol Acuphase®)	
	<u>Zuclopenthixol dihydrochloride</u>	
	Tablets	2 mg, 10 mg, 25 mg

Barnet and Chase Farm hospitals

Atypical antipsychotics

Amisulpride

Tablets	50 mg, 100mg, 200 mg, 400mg
Liquid	100mg in 1mL

Aripiprazole

Tablets	5 mg, 10 mg, 15 mg, 30 mg
Oral solution	1mg in 1mL
Injection	9.75mg in 1.3 mL (7.5mg in 1mL)

Clozapine

Note: Patient and prescriber must be registered with a suitable Clozapine Patient Monitoring Service. A Consultant Psychiatrist should initiate treatment.

Tablets	25 mg, 100 mg
---------	---------------

Olanzapine

Tablets	2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20mg
Dispersible tablets	5 mg, 10 mg, 15mg, 20 mg
Injection	10mg in 2mL

Quetiapine

Restricted for use by consultant psychiatrist only.

First-line for patient with hyperprolactinaemia and second-line in patients unresponsive to other antipsychotics

Tablets	25 mg, 100 mg, 150 mg, 200 mg, 300 mg
---------	---------------------------------------

Risperidone

Tablets	500 micrograms, 1 mg, 2 mg, 3 mg, 4 mg
Orodispersible tablets	500 micrograms, 1 mg, 2 mg, 4 mg
Liquid	1 mg in 1mL

4.2.2 Antipsychotic depot injections

Flupentixol decanoate (Flupenthixol decanoate)

Injection (oily)	20 mg in 1mL, 40 mg in 2 mL
------------------	-----------------------------

(Depixol[®])

Injection (oily)	50 mg in 0.5 mL, 100 mg in 1 mL
------------------	---------------------------------

(Depixol Conc.[®])

Injection (oily)	200 mg in 1 mL
------------------	----------------

(Depixol low volume[®])

Fluphenazine decanoate

Injection (oily)	12.5 mg in 0.5 mL, 25 mg in 1 mL, 50 mg in 0.5 mL, 100 mg in 1 mL
------------------	--

Haloperidol decanoate

Injection (oily)	50 mg in 1 mL, 100 mg in 1 mL
------------------	-------------------------------

Barnet and Chase Farm hospitals

Pipotiazine palmitate (Pipothiazine palmitate)

Injection (oily) 50 mg in 1 mL, 100 mg in 2 mL

Risperidone

Injection 25mg, 37.5mg, 50mg

Zuclopenthixol decanoate

Injection (oily) 200 mg in 1mL

(Clopixol[®])

Injection (oily) 500 mg in 1mL

(Clopixol Conc.[®])

4.2.3 Drugs used for mania and hypomania

Carbamazepine

see section 4.8.1

Valproic acid (as the semisodium salt)

Enteric coated tablets 250mg, 500mg

Lithium

Note: Different preparations vary widely in bioavailability; a change in the preparation used requires the same precautions as initiation of treatment.

Lithium carbonate

Tablets 250 mg, 400 mg

(Camcolit[®])

Tablets 200 mg, 400 mg

(Priadel[®])

Lithium citrate

Liquid (sugar free) 520 mg in 5 mL

(Priadel[®])

Please note: 5mL dose of 509mg/5mL oral solution is equivalent to 200mg lithium carbonate.

4.3 Antidepressant drugs

4.3.1 Tricyclic and related antidepressant drugs

Amitriptyline hydrochloride

Tablets 10 mg, 25 mg, 50 mg

Oral solution (sugar free) 50 mg in 5 mL

Amitriptyline and perphenazine (Triptafen[®])

Tablets Amitriptyline 25mg, perphenazine 2mg

Clomipramine hydrochloride

Capsules 10 mg, 25 mg, 50 mg

Modified release tablets 75 mg

Barnet and Chase Farm hospitals

Dosulepin hydrochloride (Dothiepin hydrochloride)

Capsules	25 mg
Tablets	75 mg
Liquid	75mg in 5mL

Doxepin

Capsules	25mg, 50mg
----------	------------

Imipramine hydrochloride

Tablets	10 mg, 25 mg
Syrup	25 mg in 5 mL

Lofepamine

Tablets	70 mg
Oral suspension	70 mg in 5 mL

Nortriptyline

Tablets	10 mg, 25 mg
---------	--------------

Trimipramine

Tablets	10mg, 25mg
Capsules	50mg

Trazodone hydrochloride

Capsules	50 mg, 100 mg
Tablets	150mg
Liquid	50 mg in 5 mL

4.3.2 Monoamine-oxidase inhibitors (MAOIs)

Isocarboxazid

Tablets	10mg
---------	------

Phenelzine

Tablets	15 mg
---------	-------

Tranlycypromine

Tablets	10 mg
---------	-------

Reversible MAOIs

Moclobemide

Tablets	150 mg, 300 mg
---------	----------------

4.3.3 Selective serotonin re-uptake inhibitors (SSRI)

Citalopram

Tablets	10 mg, 20 mg, 40 mg
Oral drops	40mg in 1mL

(Note: 4 drops (8 mg) is equivalent in therapeutic effect to 10 mg tablet)

Fluoxetine

Capsules	20 mg
Liquid	20 mg in 5 mL

Barnet and Chase Farm hospitals

Fluvoxamine maleate

Tablets 50 mg, 100 mg

Paroxetine

Tablets 20 mg, 30 mg

Liquid 10 mg in 5 mL

Sertraline

Tablets 50 mg, 100 mg

4.3.4 Other antidepressant drugs

Duloxetine (Cymbalta)

Capsules 30mg, 60mg

Duloxetine (for neuropathic pain)
Recommended as a 3rd line choice (after amitriptyline and gabapentin), by
North Central London JFC

Flupentixol (Flupenthixol)

Tablets 500 micrograms, 1 mg

Mirtazapine

Tablets 15 mg, 30 mg, 45 mg

Orodispersible tablets 15 mg, 30 mg

Reboxetine

Tablets 4mg

Venlafaxine

Tablets 37.5 mg, 75 mg

Modified release capsules 37.5mg, 75 mg, 150 mg, 225mg

4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder

Atomoxetine

Capsule 10mg, 18mg, 25mg, 40mg, 80mg

For Enfield paediatrics only, uncontrolled with methylphenidate

Dexamfetamine sulphate (dexamphetamine sulphate) (Controlled Drug)

Tablets 5mg

Methylphenidate hydrochloride (Controlled Drug)

Tablets 5 mg, 10 mg

Modified release tablets 18 mg, 27 mg, 36 mg

Modified release capsules 10 mg, 20 mg, 30 mg

Modified release preparations are only for use in ADHD patients where ordinary methylphenidate is not appropriate

Modafinil

Tablets 100 mg

Restricted for consultant neurologists only, for specific patients

Barnet and Chase Farm hospitals

4.6

Drugs used in nausea and vertigo

Antihistamines

Cinnarizine

Tablets 15 mg

Cyclizine

Tablets 50 mg

Injection 50 mg in 1 mL

Promethazine hydrochloride

See section 3.4.1

Phenothiazines and related drugs

Chlorpromazine hydrochloride

See section 4.2.1

Prochlorperazine

Tablets 5 mg

Syrup 5 mg in 5 mL

Injection 12.5 mg in 1 mL

Buccal tablets 3 mg

Domperidone and metoclopramide

Domperidone

Tablets 10 mg

Orodispersible tablets 10mg

Suspension 5 mg in 5 mL

Suppositories 30 mg

Metoclopramide hydrochloride

Tablets 10 mg

Oral solution 5 mg in 5 mL

Injection 10 mg in 2 mL

5HT₃ antagonists

Ondansetron

Tablets 4mg, 8mg

Syrup (sugar-free) 4mg in 5mL

Injection 4mg in 2mL, 8mg in 4mL

Suppositories 16mg

Barnet and Chase Farm hospitals

Hyoscine

Hyoscine hydrobromide (Scopolamine hydrobromide)

Tablets	300 micrograms
Chewable tablets	150 micrograms
Patches	1mg / 72 hours
Parenteral preparations	See Section 15.1.3

Other drugs for Ménière's disease

Betahistine dihydrochloride

Tablets	8 mg, 16mg
---------	------------

4.7

Analgesics

4.7.1

Non-opioid analgesics and compound analgesic preparations

Aspirin

Dispersible tablets	300 mg
Enteric coated tablets	300 mg
Suppositories	150 mg, 300 mg

Paracetamol

Tablets	500 mg
Soluble tablets	500 mg
Paediatric Oral Solution	120 mg in 5 mL
Oral Suspension	250 mg in 5 mL
Suppositories	60mg, 120 mg, 125mg, 240 mg, 500 mg
Infusion	1g in 100 mL (restricted to surgical wards)

For patients >33kg on recommendation of consultant anaesthetists or pain team ONLY

Co-codamol (codeine phosphate, paracetamol)

Tablets	8 mg / 500 mg, 30 mg / 500mg
Soluble tablets	8 mg / 500 mg, 30 mg / 500 mg

Co-dydramol (dihydrocodeine tartrate, paracetamol)

Tablets	10 mg / 500 mg
---------	----------------

4.7.2

Opioid analgesics

Buprenorphine (Controlled Drug)

Sublingual tablets	200 micrograms, 400 micrograms
Injection	300 micrograms in 1 mL
Patches (BuTrans [®])	'5' (releasing 5 micrograms / hour for 7 days) '10' (releasing 10 micrograms / hour for 7 days) '20' (releasing 20 micrograms / hour for 7 days)
Patches (Transtec [®])	'35' (releasing 35 micrograms / hour for 96 hours) '52.5' (releasing 52.5 micrograms / hour for 96 hours) '70' (releasing 70 micrograms / hour for 96 hours)

Barnet and Chase Farm hospitals

Codeine phosphate

Tablets	15 mg, 30 mg, 60 mg
Syrup	25 mg in 5 mL
Injection	60 mg in 1mL (Controlled Drug)

Diamorphine hydrochloride (Controlled Drug)

Tablets	10 mg
Injection	5 mg, 10 mg, 30 mg, 100 mg, 500 mg

Dihydrocodeine tartrate

Tablets	30 mg
Oral solution	10 mg in 5 mL
Injection	50 mg in 1 mL (Controlled Drug)
Modified-release tablets	60mg, 90mg

Dipipanone (Controlled Drug)

Tablets	Dipipanone hydrochloride 10mg, cyclizine hydrochloride 30mg
---------	--

Fentanyl (Controlled Drug)

Tablets (buccal)	100 micrograms, 200 micrograms, 400 micrograms, 800 micrograms
Patches	'12' (releasing 12 micrograms / hour) '25' (releasing 25 micrograms/ hour) '50' (releasing 50 micrograms/ hour) '75' (releasing 75 micrograms/ hour) '100' (releasing 100 micrograms/ hour)
Injection	See Section 15.1.4.3

Hydromorphone hydrochloride (Controlled Drug)

Capsules	1.3 mg, 2.6 mg
Modified-release capsules	2 mg, 4 mg, 8 mg, 16 mg, 24 mg

Meptazinol

Tablets	200 mg
Injection	100 mg in 1 mL

Methadone hydrochloride (Controlled Drug)

Oral solution	see section 4.10.3
Linctus	2mg in 5 mL
Tablets	5 mg
Injection	10 mg in 1mL, 50 mg in 1 mL

Barnet and Chase Farm hospitals

Morphine sulphate (Controlled Drug)

Oral solution	10 mg in 5 mL, 100 mg in 5 mL
Tablets	10 mg, 20 mg, 50 mg
Modified-release tablets (12 hour release)	5 mg, 15mg, 200mg (MST [®] brand) 10 mg, 30 mg, 60 mg, 100 mg, 200mg (Morphgesic [®] brand)
Modified-release capsules (12 hour release)	10mg, 30mg, 100mg (Zomorph [®] SR brand)
Modified-release capsules (24 hour release)	30mg, 150mg (MXL brand)
Modified-release suspension	20mg, 30mg, 60mg, 100mg, 200mg (MST brand)
Injection	10 mg in 1 mL, 15 mg in 1 mL, 30 mg in 1 mL, 50 mg in 50 mL, 100 mg in 50 mL
Preservative-free injection	2 mg in 10 mL, 4 mg in 10 mL, 10 mg in 10 mL, 100 mg in 5 mL, 40 mg in 1 mL
<i>Preservative free injection for use in elective orthopaedic patients only.</i>	
Suppositories	10mg, 15mg

Oxycodone (Controlled Drug)

Capsules	5 mg, 10 mg 20 mg
Liquid (=oral solution)	5 mg in 5 mL
Concentrate (=concentrated oral solution)	10 mg in 1 mL
Injection	10 mg 1 mL, 20mg in 2mL, 50mg in 1mL
Modified release tablet	5 mg, 10 mg, 20 mg, 30mg, 40 mg, 80 mg

Pentazocine

Capsules	50mg
----------	------

Pethidine hydrochloride (Controlled Drug)

Tablets	50 mg
Injection	50 mg in 1 mL, 100 mg in 2 mL, 50 mg in 5 mL

Preservative free injection use should include all consultant anaesthetists

Pethidine hydrochloride with Promethazine hydrochloride (Controlled Drug)

Injection	100 mg / 50 mg in 2 mL
-----------	------------------------

Tapentadol (Palexia SR[®]) – non-formulary.
Rejected by North Central London JFC.

Barnet and Chase Farm hospitals

Tramadol hydrochloride

Capsules	50 mg
Soluble tablets	50 mg
Modified-release tablets	100 mg
Injection	100 mg in 2 mL

4.7.3 Neuropathic pain

Gabapentin

See section 4.8.1

Pregabalin

See section 4.8.1

4.7.4 Antimigraine drugs

4.7.4.1 Treatment of acute migraine

Paracetamol with anti-emetics

Migraleve[®] pink tablets	Buclizine 6.25 mg, Paracetamol 500 mg, Codeine phosphate 8 mg
Migraleve[®] yellow tablets	Paracetamol 500 mg, Codeine 8 mg

Paramax[®]

Effervescent powder sachets	Paracetamol 500mg, metoclopramide 5mg
-----------------------------	--

5HT₁ agonists

Frovatriptan

Tablets	2.5mg
---------	-------

Approved for 2nd/3rd line treatment. For neurology consultant use only

Sumatriptan

Tablets	50 mg, 100 mg
Injection	6 mg in 0.5 mL
Nasal spray	10 mg in 0.1 mL, 20 mg in 0.1 mL

1st line treatment in migraine based on its cost effectiveness

Ergotamine

Inhaler	360 microgram
---------	---------------

Ergotamine with caffeine (Cafergot[®])

Tablets	ergotamine 1mg, caffeine 100mg
---------	--------------------------------

Ergotamine with Cyclizine and caffeine (Migril[®])

Tablets	ergotamine 2mg, cyclizine hydrochloride 50mg, caffeine hydrate 100mg
---------	---

Barnet and Chase Farm hospitals

4.7.4.2 **Prophylaxis of migraine**

Clonidine

Tablets 25 micrograms

Pizotifen

Tablets 500 micrograms, 1.5 mg

Methysergide

Tablets 1 mg

4.8 **Antiepileptic drugs**

4.8.1 **Control of the epilepsies**

Carbamazepine

Tablets 100 mg, 200 mg, 400 mg

Modified-release tablets 200 mg, 400 mg

Chewtabs 100 mg, 200 mg

Liquid 100 mg in 5 mL

Suppositories 125 mg, 250 mg

Oxcarbazepine

Tablets 150mg, 300 mg

Liquid 300mg in 5mL

Consultant neurologists only

Ethosuximide

Capsules 250 mg

Syrup 250 mg in 5 mL

Gabapentin

Capsules 100 mg, 300 mg, 400 mg

Lacosamide

Tablets 50 mg, 100 mg, 150 mg, 200mg

Liquid 10mg in 1mL

Lacosamide (for refractory epilepsy)
Recommended for patients refractory to standard anti-epileptic drugs, by
North Central London JFC

Lamotrigine

Tablets 25 mg, 50 mg, 100 mg

Dispersible tablets 5 mg, 25 mg, 100 mg

Barnet and Chase Farm hospitals

Levetiracetam

Tablets	250 mg, 500 mg
Oral solution	100 mg in 1 mL
Intravenous infusion	100 mg in 1 mL (5 mL vial)

Restricted to consultant neurologists as add-on therapy for partial epileptic seizures

Perampanel

Tablets	2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg
---------	--------------------------------------

Perampanel (for refractory epilepsy)
Recommended for patients refractory to standard anti-epileptic drugs, by
North Central London JFC

Phenobarbital (phenobarbitone) (Controlled Drug)

Tablets	15 mg, 30 mg, 60 mg,
Liquid (contains alcohol)	15 mg in 5 mL
Injection	see section 4.8.2

Pregabalin

Capsules	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 300 mg
----------	---

For 2nd line treatment of neuropathic pain

Primidone

Tablets	50mg, 250 mg
---------	--------------

Phenytoin

Tablets	100 mg
Capsules	25 mg, 50 mg, 100 mg, 300 mg
Chewable tablets (Infatabs [®])	50 mg
Suspension	30 mg in 5mL

Suspension of phenytoin 90 mg in 15 mL may be considered to be approximately equivalent in therapeutic effect to capsule or tablets containing phenytoin sodium 100 mg, but nevertheless care is needed in making changes.

Injection	see section 4.8.2
-----------	-------------------

Retigabine

Tablets	50mg
---------	------

Retigabine - In accordance with NICE guidance

A recommended adjunctive option for partial onset seizures with or without secondary generalisations in some people with epilepsy (TA232)

Barnet and Chase Farm hospitals

Sodium Valproate

Enteric-coated tablets	200 mg, 500 mg
Tablets (crushable)	100 mg
Liquid	200 mg in 5 mL
Modified-release tablets	200 mg, 300 mg, 500 mg

(Epilim Chrono[®])

Injection	400 mg
-----------	--------

Tiagabine

Tablets	5mg
---------	-----

Consultant neurologists only

Topiramate

Tablets	25 mg, 50 mg, 100 mg, 200 mg
---------	------------------------------

Vigabatrin

Tablets	500 mg
Powder	500 mg per sachet
(Sugar-free)	

Zonisamide

Capsules	25 mg, 50 mg, 100 mg
----------	----------------------

Approved as an adjunct therapy of partial seizures in adults with or without secondary generalisation

Benzodiazepines

Clobazam

Tablets	10 mg
---------	-------

Clonazepam

Tablets	500 micrograms, 2 mg
Liquid	500 micrograms in 5mL, 2mg in 5mL

4.8.2 Drugs used in status epilepticus

Diazepam

Injection (solution)	10 mg in 2 mL
Injection (emulsion)	10 mg in 2 mL
Rectal tubes	2.5 mg, 5 mg, 10 mg
(=Rectal solution)	

Clonazepam

Injection	1 mg in 1mL
-----------	-------------

Fosphenytoin

Injection	75mg in 1mL (≡ phenytoin sodium 50mg in 1mL)
-----------	--

Barnet and Chase Farm hospitals

Lorazepam

Injection 4 mg in 1mL

(Currently restricted to Mental Health wards due to national shortage 2010)

Midazolam

Oromucosal solution 2.5mg in 0.5mL, 5mg in 1mL, 7.5mg in 1.5mL,
10mg in 2mL

Paraldehyde in Olive Oil enema

Enema 50%

(Pharmacy keeps a ready diluted product. Note paraldehyde should not be administered undiluted)

Phenobarbital (phenobarbitone) (Controlled Drug)

Injection 15mg in 1mL, 30mg in 1mL, 60mg in 1mL,
200mg in 1mL

Phenytoin sodium

Injection 250 mg in 5 mL

4.9 Drugs used in parkinsonism and related disorders

4.9.1 Dopaminergic drugs used in Parkinson's disease

Co-beneldopa (benserazide hydrochloride, levodopa)

Capsules	62.5 (12.5/50) mg
	125 (25/100) mg
	250 (50/200) mg
Dispersible tablets	62.5 (12.5/50) mg
	125 (25/100) mg
Modified-release capsules	125 (25/100) mg

Co-careldopa (carbidopa monohydrate, levodopa)

Tablets	62.5 (12.5/50) mg
	110 (10/100) mg
	125 (25/100) mg
	275 (25/250) mg
Modified release tablets	25/100 mg, 50/200 mg

Co-careldopa with entacapone (carbidopa monohydrate, levodopa, entacapone)

Tablets	50 / 12.5 / 200 mg
	75 / 18.75 / 200 mg
	100 / 25 / 200 mg
	125 / 31.25 / 200 mg
	150 / 37.5 / 200 mg
	175 / 43.75 / 200 mg
	200 / 50 / 200mg

Barnet and Chase Farm hospitals

Amantadine

Capsules	100 mg
Syrup	50 mg in 5 mL

Bromocriptine

Capsules	5 mg, 10 mg
Tablets	1 mg, 2.5 mg

Cabergoline

Tablet	1mg, 2mg
--------	----------

Pergolide

Tablets	50 micrograms, 1mg
---------	--------------------

Pramipexole

Tablets	88 micrograms (0.125 mg salt), 180 micrograms (0.25 mg salt), 500 micrograms (0.35 mg salt), 700 micrograms (1 mg salt)
---------	--

Ropinirole

Tablets	250 micrograms, 500 micrograms, 1 mg, 2 mg, 5 mg, starter pack
---------	---

Consultant neurologists only

Rotigotine

Patches	1mg / 24 hours, 2 mg / 24 hours, 4 mg / 24 hours, 6 mg / 24hours, 8 mg / 24 hours, starter pack
---------	--

Rotigotine Patches (for Parkinson's disease)
Recommended according to local protocols, by North Central London JFC

Monoamine-oxidase-B inhibitors

Rasagiline

Tablets	1mg
---------	-----

Restricted to neurologists as 2nd line add-on therapy after failing a trial of selegiline

Selegiline hydrochloride

Tablets	5 mg, 10mg
---------	------------

Selegiline (for Parkinson's disease)
Recommended according to local protocols, by North Central London JFC

Catechol-O-methyltransferase inhibitors

Entacapone

Tablets	200 mg
---------	--------

Barnet and Chase Farm hospitals

4.9.2 Antimuscarinic drugs used in parkinsonism

Benzatropine

Injection 2mg in 2mL

Orphenadrine hydrochloride

Tablets 50 mg

Oral solution 50 mg in 5 mL

Procyclidine

Tablets 5 mg

Syrup 5 mg in 5 mL

Injection 10 mg in 2 mL

Trihexyphenidyl hydrochloride (Benzhexol hydrochloride)

Tablets 2 mg, 5 mg

Syrup 5 mg in 5 mL

4.9.3 Drugs used in essential tremor, chorea, tics, and related disorders

Riluzole

Tablets 50 mg

Tetrabenazine

Tablets 25 mg

Torsion dystonias and other involuntary movements

Botulinum A Toxin complex

Injection 100-unit vial, 500-unit vial

Funded indications:

Achalasia, Anal fissures, Axillary hyperhidrosis, Cerebral palsy, Cervical dystonia, Detrusor overactivity, Forearm dystonia, Hemifacial spasm, Severe blepharospasm

Botulinum type A - In accordance with NICE guidance
A recommended option for preventing headaches in some adults with chronic migraine (TA260)

Botulinum type A
Recommended for neurogenic bladder dysfunction in patients refractory to oral therapies, by North Central London JFC

Approved for treatment of achalasia (unlicensed indication) by BCFH D&T panel.

Recommended for diagnostic use only, for predicting patients with Sphincter of Oddi Dysfunction Type 3 who would be most likely to respond to sphincterotomy (**not for symptomatic use for patients with SOD**), by North Central London JFC

Barnet and Chase Farm hospitals

4.10 Drugs used in substance dependence

4.10.1 Alcohol dependence

Acamprosate Calcium

(For use only in patients receiving counselling)

Tablets 333 mg

Disulfiram

Tablets 200 mg

4.10.2 Nicotine dependence

Nicotine To be prescribing in accordance with NRT protocol

Nicorette Invisi[®] patches 10mg /16 hours, 15mg /16 hours, 25mg /16 hours

Nicotinell[®] patches 7 mg /24 hours, 14 mg /24 hours, 21 mg / 24 hours

Nicorette[®] inhalator 15mg

Nicorette[®] microtabs 2 micrograms

Nicorette[®] nasal spray 0.5mg per spray

Nicotinell[®] lozenges 2mg, 4mg

Gum 2mg, 4mg

Varenicline

Tablets 500micrograms, 1mg, starter pack

To be used second line along with a smoking cessation programme

4.10.3 Opioid dependence

Buprenorphine

Sublingual tablets 400 micrograms, 2mg, 4mg, 8mg

Buprenorphine with naloxone

Sublingual tablets 8mg/2mg

Lofexidine

Tablets 200 micrograms

Methadone

Liquid 1mg in 1mL

Guidance on prescribing Methadone 1 mg in 1mL

Only in exceptional circumstances should the decision to offer methadone without specialist advice be made.

Such examples may include:

- an obstetrician prescribing methadone for a drug misuser presenting with opiate withdrawal in late pregnancy,
- an A & E doctor prescribing to a patient with serious concomitant physical or psychiatric illness where withdrawal is complicating the clinical problems, and
- when there is an acute hospital admission of somebody who is opiate-dependant.

Barnet and Chase Farm hospitals

Indeed, in such circumstances it is vital that the doctor fulfil their responsibility by ensuring adequate assessment and appropriate management that facilitates the retention of the patient in treatment.

The prescribing doctor has a responsibility to ensure that the patient receives the correct dose.

Doctors should also remember that these patients may be doing a collecting round from their GP, specialist drug treatment centres or their regular pharmacy. Every effort should be made to contact the GP/specialist drug treatment centre and/or pharmacist to alert them of the patient's admission and cessation of methadone supply during the period of admission. In these circumstances the pharmacy department will supply the methadone for the length of in-patient stay.

However, where a patient wishes to obtain their own supply, it will be the responsibility of the sister or acting sister to supervise the administration of methadone in accordance with the directions of a doctor (hospital prescription). An entry should be made in the controlled drug register under the relevant section for patients own drugs brought into hospital.

At discharge a maximum of one-day supply of methadone may be prescribed and dispensed. In the case of a weekend discharge a maximum of 2-days (3-days in the case of bank holidays) may be prescribed and dispensed.

<p><u>Contact Numbers</u></p> <p><u>For patients living in the boroughs of Enfield and Barnet:</u></p> <p>Compass drug & alcohol service for Enfield (formerly Enfield Community Drugs and Alcohol Service) Telephone: 020 8344 3180 Opening hours: Monday/Wednesday 9am-4.30pm, Tuesday/Thursday/Friday 9am-6.30pm</p> <p>Barnet Drugs and Alcohol Service (BDAS) Telephone: 020 8702 4300</p> <p><u>For patients living in the borough of Harrow and Hillingdon:</u></p> <p>Compass Harrow (Drug and Alcohol services) Telephone: 0203 008 8270</p> <p>Hillingdon Drug & Alcohol Services (HDAS) Telephone: 01895 207777 Opening hours: Monday – Thursday 9am-7pm, Friday 9am – 5pm</p>

4.11

Drugs for dementia

Donepezil

Tablets	5 mg, 10 mg
Orodispersible tablet	5 mg

In accordance with NICE guidance TA217

Galantamine

Tablets	8 mg, 12 mg
Modified-release capsules	8 mg, 16 mg, 24 mg
Liquid	4mg in 1mL

In accordance with NICE guidance TA217

Barnet and Chase Farm hospitals

Rivastigmine

Capsules	1.5 mg, 3 mg, 4.5 mg, 6 mg
Oral solution	2 mg in 1 mL
Patches	4.6mg in 24 hours, 9.5mg in 24 hours

In accordance with NICE guidance TA217

Chapter 5

Infections

5 Infections

5.1 Antibacterial drugs

5.1.1 Penicillins

5.1.1.1 Benzylpenicillin and phenoxymethylpenicillin

Benzylpenicillin (Penicillin G)

Injection 600 mg, 1200mg

Phenoxymethylpenicillin (Penicillin V)

Tablets 250 mg

Oral solution 125 mg in 5 mL, 250 mg in 5 mL

5.1.1.2 Penicillinase-resistance penicillins

Flucloxacillin

Capsules 250 mg, 500 mg

Syrup 125 mg in 5 mL

Injection 250 mg, 500 mg, 1g

5.1.1.3 Broad-spectrum penicillins

Amoxicillin (Amoxycillin)

Capsules 250 mg, 500 mg

Suspension (sugar-free) 125 mg in 5 mL, 250 mg in 5 mL

Sachets (sugar-free) 3 g

Injection 250 mg, 500 mg, 1g

Co-amoxiclav (amoxicillin, clavulanic acid)

Note: The proportions are expressed in the form x/y where x and y are the strengths in the milligrams of amoxicillin and clavulanic acid respectively.

Tablets 375 mg (250/125 mg),

625 mg (500/125 mg)

Oral suspension 125/31 mg in 5 mL,

250/62 mg in 5 mL

400/57mg in 5mL

Injection 600 mg (500/100 mg),

1.2 g (1000/200 mg)

5.1.1.4 Antipseudomonal penicillins

Piperacillin with tazobactam

Injection 2.25 g, 4.5 g

Barnet and Chase Farm hospitals

5.1.2 Cephalosporins, carbapenems, and other beta-lactams

5.1.2.1 Cephalosporins

Cefalexin (cephalexin)*

Capsules	250 mg, 500mg
Oral suspension/ syrup	125 mg in 5 mL, 250 mg in 5mL

Note: restricted for inpatient use (exception in pregnancy)

Cefixime*

Tablets	200 mg
Liquid	100mg in 5mL

1st line treatment of gonorrhoea in line with national guidelines – unlicensed indication

Cefuroxime*

Injection	250 mg vial, 750 mg vial
-----------	--------------------------

Cefotaxime*

Injection	500 mg vial, 1 g vial, 2 g vial
-----------	---------------------------------

Ceftazadime*

Injection	500 mg vial, 1 g vial, 2 g vial
-----------	---------------------------------

Ceftriaxone*

Injection	250 mg vial, 1 g vial, 2 g vial
-----------	---------------------------------

***Note:** Formulary restricted – please refer to BCFH Trust Antibiotic Guidelines available on the Intranet.*

5.1.2.2 Carbapenems

Meropenem

Injection	500 mg vial, 1 g vial
-----------	-----------------------

Ertapenem

Injection	1g vial
-----------	---------

Restricted to consultant microbiologists only for the treatment of ESBL resistant infections only

5.1.3 Tetracyclines

Demeclocycline hydrochloride

Capsules	150 mg
----------	--------

Doxycycline

Capsules	50 mg, 100 mg
Soluble tablets	100mg

Doxycycline M/r capsules (Efracea) –non-formulary.
Rejected by BCFH D&T panel as cost effectiveness not demonstrated.

Lymecycline

Capsules	408 mg
----------	--------

Barnet and Chase Farm hospitals

Oxytetracycline

Tablets 250 mg

Tigecycline

Infusion 50 mg

Restricted to consultant microbiologists only

Tigecycline (Tygacil) .
Recommended for the treatment of complex multi-drug resistant bone or soft tissue infections or severe systemic infections, by North Central London JFC

5.1.4

Aminoglycosides

Gentamicin

Refer to BCFH NHS Trust Guidelines for Gentamicin once-daily prescribing and monitoring

Injection 20 mg in 2 mL, 80 mg in 2 mL

Intrathecal injection 5 mg in 1 mL

(Seek specialist advice)

Amikacin

Injection 100mg in 2mL, 500mg in 2mL

Neomycin sulphate – (restricted use)

Tablets 500 mg

Tobramycin

Injection 80mg in 2mL

5.1.5

Macrolides

Clarithromycin

Tablets 250 mg, 500mg

Suspension 125 mg in 5 mL, 250 mg in 5 mL

Intravenous infusion 500 mg vial

Erythromycin

Enteric coated tablets 250 mg, 500mg

Liquid (sugar-free) 125 mg in 5 mL, 250 mg in 5 mL,

500 mg in 5 mL

Erythromycin lactobionate

Intravenous infusion 1 g vial

Azithromycin

Capsules 250 mg

Liquid 200mg in 5mL

For Chlamydia Trachomatis infections in non-compliant patients/contacts

Barnet and Chase Farm hospitals

5.1.6

Clindamycin

Clindamycin

Capsules	150 mg
Injection	300 mg in 2 mL, 600 mg in 4 mL

5.1.7

Some other antibacterials

Chloramphenicol

(Restricted after advice from microbiology)

Capsules	250 mg
Injection	1 g vial

Fusidic acid

Sodium fusidate

Tablets	250 mg
Intravenous infusion	500 mg vial (≡ to fusidic acid 480 mg)
Suspension (fusidic acid)	250 mg in 5 mL

Note. *Fusidic acid is incompletely absorbed and doses recommended for suspension are proportionately higher than those for sodium fusidate tablets
 (750 mg fusidic acid suspension = 500 mg sodium fusidate tablet)*

Vancomycin and teicoplanin

Refer to BCFH NHS Trust Guidelines for Vancomycin prescribing and monitoring

Vancomycin

Injection	500 mg vial, 1 g vial
Capsules	125mg

Teicoplanin

Injection	200 mg vial, 400 mg vial
-----------	--------------------------

Linezolid

Tablets	600mg
Liquid	100mg in 5mL
Injection	600mg in 300mL

Colistimethate sodium

Tablets	1.5 million units
Injection (Colomycin)	1 million units

Fidaxomicin

Tablets	200mg
---------	-------

Fidaxomicin (for C.Difficile infection)

Recommended for patients with multiple recurrent infections only, by North Central London JFC

Barnet and Chase Farm hospitals

5.1.8	<u>Sulphonamides and trimethoprim</u>	
	<u>Co-trimoxazole (trimethoprim, sulfamethoxazole)</u>	
	Tablets	480 mg, 960mg
	Suspension	240 mg in 5 mL, 480 mg in 5mL
	Intravenous infusion	480 mg in 5 mL
	<u>Sulfadiazine (Sulphadiazine)</u>	
	Tablets	500mg
	<u>Trimethoprim</u>	
	Tablets	100 mg, 200 mg
	Suspension	50 mg in 5mL
5.1.9	<u>Antituberculosis drugs</u>	
	<u>Ethambutol hydrochloride</u>	
	Tablets	100 mg, 400 mg
	<u>Isoniazid</u>	
	Tablets	50 mg, 100 mg
	Injection	50mg in 2mL
	<u>Pyrazinamide</u>	
	Tablets	500 mg
	Liquid	500mg in 5mL
	<u>Rifampicin</u>	
	Capsules	150 mg, 300 mg
	Syrup	100 mg in 5 mL
	Intravenous infusion	600 mg vial
	<u>Combined preparations</u>	
	Rifater[®] tablets	Rifampicin 120 mg, Isoniazid 50 mg, Pyrazinamide 300 mg
	Rifinah[®] 150/100 tablets	Rifampicin 150 mg, Isoniazid 100 mg
	Rifinah[®] 300/150	Rifampicin 300 mg, Isoniazid 150 mg
	<u>Streptomycin</u> - (named patient only)	
	Injection	1 g vial
5.1.10	<u>Antileprotic drugs</u>	
	<u>Dapsone</u>	
	Tablets	50 mg, 100 mg+
5.1.11	<u>Metronidazole and tinidazole</u>	
	<u>Metronidazole</u>	
	Tablets	200 mg, 400 mg
	Suspension	200 mg in 5 mL
	Suppositories	500 mg, 1 g
	Intravenous infusion	500 mg in 100 mL

Barnet and Chase Farm hospitals

5.1.12 Quinolones

Ciprofloxacin

Tablets	100mg, 250 mg, 500 mg
Suspension	250 mg in 5 mL
Intravenous infusion	100 mg in 50 mL, 200 mg in 100 mL, 400 mg in 200 mL

Moxifloxacin

Tablets	400 mg
---------	--------

Moxifloxacin (for Multi-drug resistant tuberculosis, community-acquired pneumonia and acute exacerbations of chronic bronchitis)
Recommended **after microbiology approval only**, by North Central London JFC

Ofloxacin

Tablets	200 mg
---------	--------

5.1.13 Urinary tract infections

Nitrofurantoin

Tablets	100 mg
Capsules	50mg

5.2 Antifungal drugs

5.2.1 Triazole Antifungals

Fluconazole

Capsules	50 mg, 150 mg, 200 mg
Suspension	50 mg in 5 mL, 200 mg in 5 mL
Intravenous infusion	50 mg in 25 mL, 200 mg in 100 mL, 800mg in 400mL

Itraconazole

Capsules	100 mg
Oral liquid	10 mg in 1 mL

Voriconazole

Tablets	50 mg, 200 mg
Intravenous infusion	200 mg

For consultant use only as salvage therapy

5.2.3 Polyene antifungals

Amphotericin (Lipid formulation)

Intravenous infusion,	50 mg vial
-----------------------	------------

(AmBisome® - restricted use)

Barnet and Chase Farm hospitals

5.2.4 Echinocandin antifungals

Caspofungin

Intravenous infusion 50 mg vial, 70 mg vial

Approved for consultant use only as salvage therapy

5.2.5 Other antifungals

Griseofulvin

Tablets 125mg, 500mg

Liquid 125mg in 5mL

Terbinafine

Tablets 250 mg

5.3 Antiviral drugs

5.3.1 HIV infection

These drugs are ordered in on a patient-by-patient basis as required.

5.3.2 Herpesvirus infection

5.3.2.1 Herpes simplex and varicella-zoster infection

Aciclovir (Acyclovir)

Dispersible tablets 200 mg, 400 mg, 800 mg

Suspension 200 mg in 5 mL

Intravenous infusion 250 mg vial, 500 mg vial

5.3.2.2 Cytomegalovirus (CMV) infection

Cidofovir

Infusion 375mg in 5mL

Ganciclovir

Intravenous infusion 500 mg vial

(Obtained from Royal Free Hospital)

Valganciclovir

Tablets 450mg

Liquid 250mg in 5mL

5.3.3 Viral hepatitis

5.3.3.1 Chronic hepatitis B

Adefovir

Tablets 10mg

Entacavir

Tablets 500 micrograms, 1mg

In accordance with NICE guidance TA153

Barnet and Chase Farm hospitals

5.3.3.2 Chronic hepatitis C

Boceprevir

Capsules 200mg

Boceprevir - In accordance with NICE guidance
Recommended with peginterferon and ribavirin in compensated liver disease in untreated patients, or those unresponsive to previous treatment (TA253)

Telaprevir

Tablets 375mg

Telaprevir - In accordance with NICE guidance
Recommended with peginterferon and ribavirin in compensated liver disease in untreated patients, or those unresponsive to previous treatment (TA252)

Ribavarin (restricted for use in chronic hepatitis C)

Tablets (**Copegus**[®]) 200mg

Capsules (**Rebetol**[®]) 200mg

In accordance with NICE guidance TA75, TA106, TA200

5.3.4 Influenza

Oseltamivir

Capsules 30mg, 45mg, 75mg

Liquid 6mg in 1mL, 12mg in 1mL, 60mg in 5mL

5.3.5 Respiratory syncytial virus

Palivizumab

Injection 50mg, 100mg

5.4 Antiprotozoal drugs

5.4.1 Antimalarials

Artemether with Lumefantrine

Tablets 20mg artemether, 120mg lumefantrine

Chloroquine

Tablets 250 mg (= chloroquine base 155 mg)

Syrup 68 mg in 5 mL (= chloroquine base 50 mg in 5 mL)

Proguanil

Tablets 100 mg

Pyrimethamine

Tablets 25mg

Quinine sulphate

Tablets 200 mg, 300 mg

Quinine dihydrochloride

Injection 600 mg in 2 mL

Barnet and Chase Farm hospitals

5.4.8 Drugs for pneumocystic pneumonia

Pentamidine Isetionate

Restricted for consultant use only in patients in whom co-trimoxazole is contraindicated

Nebuliser solution 300mg

5.5 Anthelmintics

5.5.1 Drugs for threadworms

Mebendazole

Tablets 100 mg

Suspension 100 mg in 5 mL

Piperazine with sennosides

Oral powder 4g piperazine, 15.3mg sennosides per sachet

5.5.3 Drugs for tapeworm infections

Albendazole

Tablets (*unlicensed*) 400 mg

Praziquantel

Tablets (*unlicensed*) 150mg, 600mg

Chapter 6
Endocrine system

6 Endocrine system

6.1 Drugs Used in Diabetes

6.1.1 Insulins

6.1.1.1 Short-acting insulins

Soluble insulin

Human Actrapid[®] 10 mL vial

Humulin S[®] 10 mL vial

Hypurin[®] Porcine Neutral 10 mL vial

Hypurin[®] Bovine Neutral 10 mL vial

Insulin analogues

Insulin aspart

NovoRapid[®] 10 mL vial, 3 mL FlexPen, cartridges

Insulin lispro

Humalog[®] 10 mL vial, 3 mL Kwikpen

Insulin glulisine

Apidra[®] 3 mL Solostar prefilled pen

6.5.3.2 Intermediate- and long-acting insulins

Insulin detemir (Recombinant human insulin analogue – long acting)

Levemir[®] 3 mL FlexPen, penfill cartridge, innolet

For type 1 diabetics who suffer repeated nocturnal hypoglycaemia, patients who need twice daily isophane insulin, patients with inadequate control despite optimal use of existing insulins

Insulin glargine (Recombinant human insulin analogue – long acting)

Lantus[®] 10 mL vial, 3 mL Solostar prefilled pen

For type 1 diabetics who suffer repeated nocturnal hypoglycaemia, patients who need twice daily isophane insulin, patients with inadequate control despite optimal use of existing insulins

Isophane insulin – intermediate acting

Insulatard[®] 10 mL vial

Humulin I[®] 10 mL vial, 3 mL Kwikpen

Biphasic insulins

Biphasic insulin aspart

NovoMix[®] 30 3 mL FlexPen

Biphasic insulin aspart

Humalog[®] Mix 25 3 mL Kwikpen

Humalog[®] Mix 50 3 mL Kwikpen

Barnet and Chase Farm hospitals

	<u>Biphasic isophane insulin</u>	
	Hypurin[®] Porcine 30/70 Mix	10 mL vial
	Humulin M3[®]	10 mL vial, 3 mL Kwikpen
6.5.3.3	Hypodermic equipment	
	<u>Autopen[®] 24</u>	(1 unit version)
	<u>Autopen[®] 24</u>	(2 unit version)

6.5.4 **Antidiabetic drugs**

6.5.4.1 **Sulphonylureas**

Glibenclamide

Tablets 2.5 mg, 5 mg

Gliclazide

Tablets 80 mg

Glimepiride

Tablets 1 mg, 2 mg, 3 mg

Glipizide

Tablets 2.5mg, 5mg

Tolbutamide

Tablets 500 mg

6.5.4.2 **Biguanides**

Metformin

Tablets 500 mg, 850 mg

Modified-release tablets 500mg, 750 mg

Oral powder 500 mg, 1 g

6.5.4.3 **Other antidiabetics**

Acarbose

Tablets 50 mg, 100 mg

Dapagliflozin

Tablets 5 mg, 10 mg

In line with treatment protocol

Dapagliflozin - In accordance with NICE guidance

A recommended option in combination for treating type 2 diabetes (TA288)

A recommended option in combination with insulin with or without other antidiabetic drugs for treating type 2 diabetes (TA288)

NOT recommended in combination with metformin and a sulphonylurea as triple therapy for treating type 2 diabetes, unless part of a clinical trial (TA288)

Barnet and Chase Farm hospitals

Exenatide

Prolonged-release injection 2mg/dose

(Bydureon®)

For second line use when Liraglutide is not suitable or in patients that cannot tolerate daily injections

Exenatide prolonged release (Bydureon®)- In accordance with NICE guidance

A recommended option in combination with oral drugs for selected patients with type 2 diabetes (TA248)

Exenatide (Byetta®) – Non-formulary

Exenatide (Byetta) twice daily dosing injection has been **removed from the Trust formulary** as liraglutide is now 1st line treatment, with Exenatide (Bydureon) once weekly dosing injection as 2nd line, by North Central London JFC

Liraglutide

Injection 6 mg in 1 mL

For consultant endocrinologist initiation only. 1st line GLP-1receptor agonist.

Pioglitazone

Tablets 15 mg, 30 mg, 45mg

Repaglinide

Tablets 500 micrograms, 1 mg, 2 mg

Sitagliptin

Tablets 25mg, 50mg, 100 mg

In line with NICE guidance CG87

Saxagliptin

Tablets 2.5mg, 5mg

In line with NICE guidance CG87

6.1.4

Treatment of hypoglycaemia

Glucose gel

Note. Glucose 10 g is available from 2 teaspoons sugar, 3 sugar lumps, milk 200 mL, and non-diet version of *Lucozade® Sparkling Glucose Drink* 50-55 mL, *Coca-Cola®* 90 mL, *Ribena® Original* 15 mL (to be diluted).

GlucoGel® 10 g glucose/ 25 g oral ampoule

(Formerly known as **Hypostop®** Gel)

DextroGel® 25g

Barnet and Chase Farm hospitals

Glucagon

GlucaGen[®] Hypokit

Injection 1 mg vial

Glucose

Intravenous infusion 20 % (500 mL)

6.1.5 Treatment of diabetic nephropathy and neuropathy

Duloxetine

Capsules 30 mg, 60 mg (**Cymbalta[®]**)

Approved for painful diabetic neuropathy as second line if patient fails to respond to amitriptyline

6.1.6 Diagnostic and monitoring agents for diabetes mellitus

Blood glucose monitoring strips

Accucheck[®] Active, Accucheck[®] Aviva, Optium[®] Plus, Optium[®] H

Urinalysis

Diastix[®] – *Reagent strips*, for detection of glucose in urine

Ketostix[®] – *Reagent strips*, for detection of ketones in urine

Other reagent strips

Multistix[®] SG, Multistix[®] 8SG

6.2 Thyroid and antithyroid drugs

6.2.1 Thyroid hormones

Levothyroxine sodium (Thyroxine sodium)

Tablets 25 micrograms, 50 micrograms,
100 micrograms

Liothyronine sodium (L-Tri-iodothyronine sodium)

Tablets 20 micrograms
Injection 20 micrograms

6.2.2 Antithyroid drugs

Carbimazole

Tablets 5 mg, 20 mg

Propylthiouracil

Tablets 50 mg

6.3 Corticosteroids

6.3.1 Replacement therapy

Fludrocortisone acetate

Tablets 100 micrograms

Barnet and Chase Farm hospitals

6.3.2

Glucocorticoid therapy

Prednisolone

Tablets	1 mg, 5 mg, 25 mg
Enteric coated tablets	2.5 mg
Soluble tablets	5 mg

Soluble tablets restricted for use in paediatrics only

Betamethasone

Tablets	500 micrograms
Injection	4 mg in 1 mL

Deflazacort

Tablets	6 mg
---------	------

Dexamethasone

Tablets	500 micrograms, 2 mg
Oral solution	2 mg in 5 mL
Injection	4 mg in 1 mL, 8mg in 2mL

Hydrocortisone

Tablets	10 mg, 20 mg
---------	--------------

Hydrocortisone sodium succinate

Injection	100 mg vial
-----------	-------------

Hydrocortisone sodium phosphate

Injection	100 mg in 1 mL
-----------	----------------

Methylprednisolone

Tablets	2 mg, 4 mg, 100 mg
---------	--------------------

Methylprednisolone sodium succinate

Injection	40 mg, 125 mg, 500 mg, 1g, 2g
-----------	-------------------------------

Methylprednisolone acetate

Injection	40 mg in 1 mL, 80 mg in 2 mL, 120 mg in 3 mL
-----------	--

Triamcinolone

Injection (vial)	10 mg in 1 mL, 40 mg in 1 mL
Injection (pre-filled syringe)	40 mg in 1 mL

6.4

Sex hormones

6.4.1 Female sex hormones and their modulators

6.4.1.1 Oestrogens and HRT

Barnet and Chase Farm hospitals

Women with uterus

The following preparations contain a **progestogen** as well as an **oestrogen** and are therefore suitable for a woman with an **intact uterus**; they are **not** suitable for use as (or with) hormonal contraceptives.

Product name	Product constituents
Premique [®] tablets	Conjugated oestrogen 625 micrograms and medroxyprogesterone acetate 5mg
Premique [®] Low Dose tablets	Conjugated oestrogen 300 micrograms and medroxyprogesterone acetate 1.5mg
Prempak-C [®] 0.625 tablets	Conjugated oestrogens 625 micrograms and norgestrel 150 micrograms (≡ levonorgestrel 75 micrograms)
Prempak-C [®] 1.25 tablets	Conjugated oestrogens 1.25 mg and norgestrel 150 micrograms (≡ levonorgestrel 75 micrograms)
Climesse [®] tablets	Estradiol valerate 2mg and norethisterone 700 micrograms
Climagest [®] 2 mg tablets	Estradiol 1mg and and Estradiol valerate 2 mg and norethisterone 1 mg
Cyclo-Progynova [®] 2 mg tablets	Estradiol valerate 2 mg and Estradiol valerate 2 mg with norgestrel 500 micrograms (≡levonorgestrel 250 micrograms)
Evorel Conti [®] patches	(releasing estradiol approx. 50 micrograms/24 hours and norethisterone acetate approx. 170 micrograms/ 24 hours)
Femoston-conti [®] tablets	Estradiol 1mg and dydrogesterone 5mg
Kliofem [®] tablets	Estradiol 2 mg and norethisterone acetate 1 mg
Kliovance [®] tablets	Estradiol 1 mg and norethisterone acetate 500 micrograms
Tridestra [®] tablets	Estradiol 2mg and Estradiol 2mg and medroxyprogesterone acetate 20mg and inactive tablets

Women without a uterus

The following preparations do **not** contain a **progestogen**; if the uterus is intact they need to be given with a progestogen in which case packs incorporating a suitable progestogen tablet are preferred (see above).

Conjugated oestrogens only

Premarin[®]

Tablets 625 micrograms, 1.25 mg

Estradiol only

Estradiol

Patches 25micrograms/24hours, 50micrograms/24hours, 75micrograms/24hours, 100micrograms/24hours

Tablets 1mg, 2 mg

(Progynova[®], Elleste Solo[®])

Raloxifene

Barnet and Chase Farm hospitals

Tablets 60mg

Tibolone

Tibolone combines oestrogenic and progestogenic activity with weak androgenic activity.

Tablets 2.5 mg

Ethinylestradiol (Ethinylestradiol)

Tablets 10 micrograms, 50micrograms, 1mg

6.4.1.2 Progestogens and progesterone receptor modulators

Dydrogesterone

Tablets 10 mg

Medroxyprogesterone acetate

Tablets 5 mg, 10 mg

Norethisterone

Tablets 5 mg

Progesterone

Pessaries 200 mg, 400 mg

Injection 50 mg in 1 mL, 100mg in 2mL

Ulipristal (Esyma®)

Tablet 5mg

Ulipristal (for uterine fibroids)

Recommended as a first-line option in place of GNRH analogues by North Central London JFC

6.4.2 Male sex hormones and antagonists

Testosterone and esters

Testosterone enantate

Injection (oily) 250 mg in 1 mL

Testosterone undecanoate

Injection (oily) 1000mg in 4 mL

Testosterone propionate

Injection 100 mg in 2 mL

Sustanon 250® Injection

(Oily) Testosterone propionate 30 mg,
Testosterone phenylpropionate 60 mg,
Testosterone decanoate 100 mg in 1 mL

Gel (**Tostran®**) 2%

Approved as 2nd line when injection is not suitable

Implant 100 mg

Patches (**Andropatch®**) 2.5 mg in 24 hours

Anti-androgens

Cyproterone acetate

Barnet and Chase Farm hospitals

Tablets 50 mg, 100mg

Dutasteride

Capsules 500 micrograms

2nd line after treatment failure with finasteride

Finasteride

Tablets 1mg, 5 mg

6.4.3 Anabolic steroids

Nandrolone

Injection 50mg in 1mL

6.5 Hypothalamic and pituitary hormones and anti-oestrogens

6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogens

Anti-oestrogens

Clomifene citrate (Clomiphene citrate)

Tablets 50 mg

Anterior pituitary hormones

Corticotrophins

Tertacosactide (Tetracosactrin)

Injection (as acetate) 250 micrograms in 1 mL

Injection (as acetate), 1 mg in 1 mL

Gonadotrophins

Chorionic gonadotrophin

(Human Chorionic Gonadotrophin, HCG)

Injection 1500 unit amp, 5000 unit amp

Hypothalamic hormones

Gonadorelin

(Gonadotrophin-releasing hormone; GnRH; LH-RH)(HRF)

Injection 100-microgram vial

Growth hormones

Somatropin

Injection (**Genotropin**[®]) 5.3 mg (16 unit) cartridge,
12mg (36 unit) cartridge

Injection (**Norditropin**[®]) 5mg, 10mg, 15mg

Injection (**Omnitropin**[®]) 5mg in 1.5mL, 10mg in 1.5mL

Injection (**Saizen**[®]) 12mg (36 unit) cartridge, 20 mg (60 unit) cartridge
8mg (24 unit) vial

Barnet and Chase Farm hospitals

Injection (**Zomacton**[®]) 4mg (12 unit) vial

6.5.2

Posterior pituitary hormones and antagonists

Posterior pituitary hormones

Vasopressin

(Argipressin – synthetic vasopressin)

Injection 20 units in 1 mL

Desmopressin

Tablets 100 micrograms, 200 micrograms

Sublingual tablets 120micrograms, 240 micrograms

Intranasal solution 100 micrograms in 1 mL

Nasal spray 10 micrograms per metered spray,
150 micrograms per metered spray

Injection 4 micrograms in 1 mL, 15mg in 1mL

Terlipressin

Injection 1 mg vial

Tolvaptan

Tablets 15mg

For symptomatic hyponatraemia secondary to SIADH

6.6

Drugs affecting bone metabolism

6.6.1

Calcitonin and parathyroid hormone

Calcitonin (salmon)/ Salcatonin

Injection 50 units in 1 mL, 100 units in 1 mL

Teriparatide

Injection 250 micrograms in 1 mL

Restricted to rheumatology only. Usage in line with NICE guidanceTA161

6.6.2

Bisphosphonates and other drugs affecting bone metabolism

Alendronic acid

Alendronic acid should be the 1st line bisphosphonate. All suitable patients should be switched from risedronate to alendronate.

Exclusions to switch are:

- *Drug intolerance*
- *GORD*
- *Crohn's disease*

Tablets 70 mg (once weekly)

Tablets 10mg daily (*for steroid induced osteoporosis in men, licensed dose for this indication is 5mg*)

Barnet and Chase Farm hospitals

Disodium etidronate

Tablets 200 mg

Didronel PMO[®] tablets Disodium etidronate 400 mg,
Calcium carbonate 1.25 g

Disodium pamidronate

Injection 15 mg, 30 mg, 90 mg

Strontium ranelate (for osteoporosis)

Withdrawn from formulary by North Central London JFC, due to EMEA safety concerns

Ibandronic acid

Approved for patients where compliance with weekly preparations is problematic. Licensed indication is only for the treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral fractures

Tablets 150 mg

Ibandronic acid (for prevention of skeletal events)

Recommended for as an option for prevention of skeletal events in patients with breast cancer and bone metastases, by North Central London JFC

Sodium clodronate

Capsules 400 mg

Tablets 520 mg, 800 mg

Intravenous solution 300 mg in 5 mL

(Concentrate)

Zoledronic acid

Injection 4 mg

4mg vials to be used for all indications – 2 x 4mg vials are to be used to obtain a 5mg dose where necessary

*Treatment of tumour-induced hypercalcaemia and prevention of SRE in patients with multiple myeloma and breast cancer. **Not approved** for preventing SRE in prostate cancer*

Approved for treatment of Paget's disease

Approved for treatment of osteoporosis

Barnet and Chase Farm hospitals

Denosumab

Injection 60 mg in 1 mL

Denosumab - In accordance with NICE guidance

A recommended option instead of a bisphosphonate for preventing skeletal-related events caused by bone metastases from solid tumours.

Not recommended for bone metastases from prostate cancer. (TA265)

6.7

Other endocrine drugs

6.7.1

Bromocriptine and other dopamine-receptor stimulants

Bromocriptine

Tablets 1 mg, 2.5 mg

Capsules 5 mg, 10 mg

Cabergoline

Tablets 500 micrograms

6.7.2

Drugs affecting gonadotrophins

Danazol

Capsules 100 mg, 200 mg

Gonadorelin analogues

Goserelin

For preparations see section 8.3.4.2

Triptorelin

For preparations see section 8.3.4.2

Approved for treatment of precocious puberty

Nafarelin

Nasal spray (as acetate) 200 micrograms per metered dose

6.7.3

Metyrapone

Metyrapone

Capsules 250mg

Chapter 7

Obstetrics, gynaecology, and urinary-tract disorders

7 **Obstetrics, gynaecology, and urinary-tract disorders**

7.1 **Drugs used in Obstetrics**

7.1.1 **Prostaglandins and oxytocics**

Carboprost

Injection 250 micrograms in 1 mL

Dinoprostone

Vaginal tablets (**Prostin**[®]) 3 mg

Pessaries (**Propess**[®]) 10 mg per 24 hours

To be used for induction of pregnancy particularly in low risk pregnancies

Intravenous solution 0.75 mg in 0.75 mL

Extra amniotic solution 10mg in 1mL

Vaginal gel 1 mg, 2 mg

Ergometrine maleate

Injection 500 micrograms in 1 mL

Ergometrine maleate with oxytocin

(Syntometrine[®])

Injection Ergometrine 500 micrograms, oxytocin 5 units;
in 1 mL

Gemeprost

Pessaries 1 mg

Oxytocin

(Syntocinon[®])

Injection 5 units in 1 mL, 10 units in 1 MI

7.1.1.1 **Drugs affecting the ductus arteriosus**

Maintenance of patency

Alprostadil

Intravenous solution 500 micrograms in 1 mL

For dilution and use as an infusion

7.1.2 **Mifepristone**

Mifepristone

A doctor who has been trained in administering Mifepristone may only prescribe the tablets. From 1st June 1997 all senior house officers and registrars (except locum doctors) in obstetrics and gynaecology will have been trained as part of their induction programme.

Tablets 200 mg

Barnet and Chase Farm hospitals

7.1.3 **Myometrial relaxants**

Atosiban

Injection 6.75 mg in 0.9 mL

Injection 37.5 mg in 5 mL

For high risk patients, to delay preterm labour

Ritodrine hydrochloride

Tablets 10 mg

7.2 **Treatment of vaginal and vulval conditions**

7.2.1 **Preparations for vaginal and vulval changes**

Oestrogens, topical

Conjugated oestrogens (equine)

(Premarin[®])

Vaginal cream 625 micrograms per gram

Estriol

Intravaginal Cream (**Ovestin[®]**) 0.1 %

Intravaginal cream (**Gynest[®]**) 0.01 %

Pessaries (**Ortho-Gynest[®]**) 500micrograms

Vaginal tablets (**Vagifem[®]**) 10micrograms, 25micrograms

7.2.2 **Vaginal and vulval infections**

Preparations for vaginal and vulval candidiasis

Clotrimazole

Cream 1 %, 2 %

Vaginal Cream 10 %

Pessaries 100mg, 200mg, 500 mg

Econazole

Pessaries 150mg

Ketoconazole

Cream 2 %

Miconazole

Cream 2%

Preparations for other vaginal infections

Clindamycin

Cream 2%

Metronidazole (Zidoval[®])

Vaginal Gel 0.75 %

Barnet and Chase Farm hospitals

7.3 **Contraceptives**

7.3.1 **Combined oral contraceptives**

<u>Low strength</u> Contraceptives	Product constituents
Loestrin 20 [®] tablets	norethisterone 1 milligram ethinylestradiol 20 micrograms
Mercilon [®] tablets	desogestrel 150 micrograms, ethinylestradiol 20 micrograms
Millinette [®] 20/75 tablets	Gestodene 75 micrograms, ethinylestradiol 20 micrograms

<u>Standard strength</u> Contraceptives	Product constituents
<u>Ethinylestradiol with Levonorgestrel</u>	
Triregol [®] tablets	6 pink tablets, ethinylestradiol 30 micrograms, levonorgestrel 50 micrograms; 5 white tablets, ethinylestradiol 40 micrograms, levonorgestrel 75 micrograms; 10 ochre tablets, ethinylestradiol 30 micrograms, levonorgestrel 125 micrograms
Microgynon 30 ED [®] tablets	levonorgestrel 150 micrograms, ethinylestradiol 30 micrograms
Levest [®] tablets	levonorgestrel 150 micrograms, ethinylestradiol 30 micrograms
<u>Ethinylestradiol with Norethisterone</u>	
Brevinor [®] tablets	norethisterone 500 micrograms, ethinylestradiol 35 micrograms
Norimin [®] tablets	norethisterone 1 mg, ethinylestradiol 35 micrograms
Trinovum [®] tablets	7 white tablets-ethinylestradiol 35 micrograms, norethisterone 500 micrograms 7 light peach tablets-ethinylestradiol 35 micrograms, norethisterone 750 micrograms 7 peach tablets- ethinylestradiol 35 micrograms, norethisterone 1 milligram
<u>Ethinylestradiol with Norgestimate</u>	
Cilest [®] tablets	norgestimate 250 micrograms, ethinylestradiol 35 micrograms
<u>Ethinylestradiol with Desogestrel</u>	
Marvelon [®] tablets	desogestrel 150 micrograms, ethinylestradiol 30 micrograms
<u>Ethinylestradiol with Drospirenone</u>	
Yasmin [®] tablets	Drospirenone 3mg, Ethinylestradiol 30 micrograms
<u>Ethinylestradiol with Gestodene</u>	
Millinette [®] tablets 30/75	gestodene 75 micrograms, ethinylestradiol 30 micrograms
<u>Estradiol with Dienogest</u>	
Qlaira [®] tablets	2 active tablets, estradiol valerate 3mg; 5 active tablets, estradiol valerate 2mg, dienogest 2mg; 17 active tablets, estradiol valerate 2mg, dienogest 3mg; 2 active tablets, estradiol valerate 2mg; 2 inactive tablets

Barnet and Chase Farm hospitals

Ethinylestradiol with Norelgestromin

Patch (**Evra**[®]) releasing ethinylestradiol approx. 33.9 micrograms/24 hours and norelgestromin approx. 203 micrograms/24 hours.

Ethinylestradiol with Etonogestrel

Vaginal ring (**Nuvaring**[®]) releasing ethinylestradiol approx. 15 micrograms/24 hours and etonogestrel approx. 120 micrograms/24 hours

7.3.2 Progestogen-only contraceptives

7.3.2.1 Oral progestogen-only contraceptives

Femulen[®] tablets etynodiol diacetate 500 micrograms
Microval[®] tablets levonorgestrel 30 micrograms
Cerazette[®] tablets desogestrel 75 micrograms
Micronor[®] tablets Norethisterone 350micrograms

7.3.2.2 Parenteral progestogen-only contraceptives

Medroxyprogesterone acetate

(Depo-Provera[®])

Injection 150 mg in 1 mL

Etonogestrel

(Nexplanon[®]) – *restricted for Clare Simpson house in-patients unable to use oral contraceptives*

Implant 68mg

7.3.2.3 Intra-uterine progesterone-only device

Intra-uterine system (**Mirena**[®]) releasing levonorgestrel 20 micrograms over 24 hours

7.3.3 Spermicidal contraceptives

Nonoxynol-9 gel 2%

7.3.4 Contraceptive devices

T-safe CU 380 Intra-uterine device

7.3.5 Emergency contraception

Levonorgestrel

(Levonelle[®])

Tablet 1.5mg

Ulipristal acetate

(ellaOne[®])

Tablet 30mg

Barnet and Chase Farm hospitals

7.4 Drugs for genito-urinary disorders

7.4.1 Drugs for urinary retention

Alpha-blockers

Alfuzosin

Modified release tablets 10mg

For the treatment of benign prostatic hyperplasia

Doxazosin

See section 2.5.4

Indoramin

Tablets 20 mg

Tamsulosin

Modified release capsules 400 micrograms

Combidart (Tamsulosin and dutasteride combined preparation) –non-formulary. Not approved by BCFH D&T panel as individual preparations are already available and recommend not prescribing combined products. Lack of evidence of head-to-head studies comparing dutasteride/tamsulosin and finasteride/tamsulosin preparations.

7.4.2 Drugs for urinary frequency, enuresis, and incontinence

Urinary incontinence

Duloxetine – non-formulary for urology and gynaecology
 Not approved by BCFH D&T panel as clinicians failed to present evaluation results after 6 month trial period.

 Approved for neuropathic pain indications in accordance with NICE guidance.

Flavoxate hydrochloride

Tablets 200 mg

Mirabegron

Tablets 25 mg, 50 mg

Mirabegron (Betmiga) - In accordance with NICE guidance

 A recommended option for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects (TA290)

Barnet and Chase Farm hospitals

Oxybutynin hydrochloride

Tablets	2.5 mg, 3 mg, 5 mg
Modified release tablets	5 mg, 10 mg
Elixir	2.5 mg in 5 mL

Oxybutynin patches – non-formulary

Initially approved by BCFH D&T subject to prescribing guideline being produced and approved. Guidelines never approved, so removed from formulary.

Solifenacin

Tablets	5mg, 10mg
---------	-----------

Tolterodine tartrate

Tablets	1mg, 2mg
Modified release capsules	4mg

Trospium chloride

Tablets	20 mg
---------	-------

Fesoterodine – non-formulary

Removed from formulary on advice of North central London JFC

7.4.3 **Drugs used in urological pain**

Alkalinisation of urine

Potassium citrate

Mixture BP	30 % (28 mmol K ⁺ / 10 mL)
Tablets	1.5 g (14 mmol K ⁺ per tablet)

7.4.4 **Bladder instillations and urological surgery**

Interstitial cystitis

Dimethyl sulfoxide (dimethyl sulphoxide)

(Rimso 50[®]) – named patient basis only

Bladder instillation	50 % (50 mL)
----------------------	--------------

Sodium hyaluronate (Hycyst[®])

Intravesical Injection	50mL
------------------------	------

Restricted for use in interstitial cystitis only

Urological surgery

Glycine

Irrigation solution	1.5 % (3 L)
---------------------	-------------

Sodium chloride

Bladder irrigation	0.9% (1L, 3L)
--------------------	---------------

Barnet and Chase Farm hospitals

Maintenance of indwelling urinary catheters

Catheter patency solutions

Chlorhexidine 0.02 %

(Uro-Tainer Chlorhexidine[®]) 100 mL sachet

Sodium chloride 0.9 %

(Uro-Tainer M[®] Sodium Chloride) 100 mL sachet

Solution G

(Uro-Tainer Suby G[®]) 100 mL sachet

7.4.5 **Drugs for erectile dysfunction**

Alprostadil and Sildenafil may **only** be prescribed on the NHS to those men suffering from erectile dysfunction and have any of the following medical conditions:

*Diabetes,
Multiple sclerosis,
Parkinson's disease,
Poliomyelitis,
Prostate cancer,
Prostatectomy (including TURP),
Radical pelvic surgery,
Renal failure treated by dialysis or transplant,
Severe pelvic injury,
Single gene neurological disease,
Spinal cord injury,
Spina bifida*

Reference: HSC 1999/148

Alprostadil

Intracavernosal injection

(Caverject [®])	5-microgram vial 10-microgram cartridge (for doses 2.5-10 micrograms), 20-microgram cartridge (for doses 5-20 micrograms)
(Viridal Duo [®])	10mcg starter and continuation packs 20mcg starter and continuation packs 40mcg starter and continuation packs
Urethral application (MUSE [®])	250 micrograms, 500 micrograms, 1 mg

Sildenafil

Tablets 25 mg, 50 mg, 100 mg

Papaverine

Injection 30mg in 2mL, 40 mg in 1 mL

Phentolamine

See section 2.5.4

Vardenafil

Tablets 5 mg, 10 mg, 20 mg

Chapter 8

Malignant disease and immunosuppression

8 Malignant disease and immunosuppression

8.1 Cytotoxic drugs

Notes

- Trained personnel should reconstitute cytotoxics; Reconstitution should be carried out in designated areas;
- Pregnant staff should not handle cytotoxics;
- Adequate care should be taken in the disposal of waste material, including syringes, containers, and absorbent material.

Drugs for cytotoxic-induced side-effects

Methotrexate-induced mucositis and myelosuppression

Calcium folinate (calcium leucovorin)

Tablets	15 mg
Injection	15mg in 2mL, 30 mg in 10 mL, 350mg in 35mL

Urothelial toxicity

Mesna

Tablets	400 mg, 600 mg
Injection	1000 mg in 10 mL

Note: If required for oral administration contents of ampoule may be taken in a flavoured drink such as orange juice or cola which may be stored in a refrigerator for up to 24 hours in a sealed container

8.1.1 Alkylating drugs

Bendamustine

Injection	25mg, 100mg
-----------	-------------

Bendamustine (for multiple myeloma)

Recommended according to local protocols, by North Central London JFC

Busulfan (Busulphan)

Tablets	2 mg
---------	------

Chlorambucil

Tablets	2 mg
---------	------

Cyclophosphamide

Tablets	50 mg
Injection	500 mg, 1g

Estramustine

Capsules	140 mg
----------	--------

Ifosfamide

Injection	1g, 2g
-----------	--------

Melphalan

Tablets	2 mg
Injection	50 mg

Barnet and Chase Farm hospitals

Treosulphan

Capsules 250mg

8.1.2 Anthracyclines and other cytotoxic antibiotics

Bleomycin

Injection 15 000 unit

Daunorubicin

Injection 20 mg

Doxorubicin hydrochloride

Injection 10 mg, 20mg, 50 mg

Epirubicin hydrochloride

Injection 10 mg in 5mL, 50 mg in 25mL, 100 mg in 50mL

Bladder instillation 50 mg in 50 mL

(Unlicensed preparation – reconstituted in pharmacy)

Idarubicin hydrochloride

Capsules 5 mg, 10 mg, 25 mg

Injection 10 mg

Mitomycin

Injection 10 mg, 20mg, 40 mg

Bladder instillation 40 mg in 40 mL

Mito-in for use on select wards for single instillation following TURBT. Courses of Mitomycin C will still be made by pharmacy

Mitoxantrone (Mitozantrone)

Concentrate for 20 mg in 10 mL

Approved as second line adjuvant therapy for multiple sclerosis after patient has failed 1st line treatment (glatiramer or interferon-beta)

8.1.3 Antimetabolites

Azacitidine

Injection 100mg

Capecitabine

Tablet 150 mg, 500mg

3rd line monotherapy in patients with metastatic breast cancer

Capecitabine- In accordance with NICE guidance

Bevacizumab and capecitabine

Not recommended for first line treatment of metastatic breast cancer when other chemotherapy (inc. taxanes, anthracyclines) is not appropriate, or if taxanes or anthracyclines given in past 12 months (TA263)

Cladribine

Injection 2mg in 1mL, 10mg in 10mL

Barnet and Chase Farm hospitals

Cytarabine

Injection 100 mg in 5 mL

(For intravenous, subcutaneous and intrathecal use)

Injection 1 g in 10 mL, 2mg in 20mL, 500mg in 5mL

(For intravenous and subcutaneous use)

Fludarabine phosphate

Tablets 10 mg

Injection 50 mg

Fluorouracil

Injection 250mg in 10mL, 500mg in 20mL, 1000mg in 20mL

Gemcitabine

Injection 200mg

Mercaptopurine

Tablets 50 mg

Methotrexate

Tablets 2.5 mg

Injection 5mg in 2mL, 50 mg in 2 mL, 500 mg in 20 mL,

1g in 10mL, 5 g in 50 mL

Pemetrexed

Injection 100mg, 500mg

Tioguanine (Thioguanine)

Tablets 40 mg

8.1.4 **Vinca alkaloids and etoposide**

Etoposide

Capsules 50 mg, 100 mg

Infusion 70mg

Concentrate for i.v. infusion 100 mg in 5 mL

Note Vinblastine, vincristine and vinorelbine are for **intravenous administration only**.

Inadvertent intrathecal administration can cause severe neurotoxicity, which is usually

fatal.

Vinblastine sulphate

Injection 10 mg in 10 mL

Infusion 10mg in 50mL

Vincristine sulphate

Injection 1 mg in 1mL, 2 mg in 2 mL

Infusion 2mg in 50mL

Vinorelbine

Capsules 20mg, 30mg, 80mg

Injections 10mg in 1 mL, 50mg in 5mL

In line with NICE guidance CG81

Barnet and Chase Farm hospitals

8.1.5 **Other antineoplastic drugs**

Amsacrine

Injection 75mg in 1.5mL

Bevacizumab

Injection 100mg in 4mL, 400mg in 16mL,
1.25mg in 0.05mL

Bevacizumab- In accordance with NICE guidance

Not recommended in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

Not recommended in combination with gemcitabine and carboplatin for first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

Not recommended for Colorectal cancer (metastatic) (TA242)

Not recommended in combination with capecitabine for first line treatment of metastatic breast cancer when other chemotherapy (inc. taxanes, anthracyclines) is not appropriate, or if taxanes or anthracyclines given in past 12 months (TA263)

Bortezomib

Injection 3.5mg

Bortezomib - In accordance with NICE guidance

A recommended option for multiple myeloma (first line) only if not tolerated or suitable (TA228)

Crisantaspase (Asparaginase)

Injection 10000 unit vial
(Erwinase[®])

Dacarbazine

Injection 100 mg vial, 200 mg vial, 500 mg vial,
1000 mg vial

Hydroxycarbamide/ Hydroxyurea

Capsules 500 mg

Barnet and Chase Farm hospitals

Ipilimumab

Concentrate for intravenous infusion 50mg in 10mL

Ipilimumab- In accordance with NICE guidance

Recommended as an option for treating advanced (unresectable or metastatic) melanoma in people who have received prior therapy, only if the manufacturer provides the discount agreed in the patient access scheme (TA268)

Platinum compounds

Carboplatin

Injection 150mg in 15mL, 450mg in 45mL, 600mg in 60mL

Cisplatin

Injection 10mg in 10mL, 50 mg in 50 mL, 100mg in 100mL

Oxaliplatin

Injection 50mg, 100mg

Procarbazine

Capsules 50 mg

Tretinoin

Capsules 10 mg

Protein kinase inhibitors

Dasatinib

Tablets 20mg, 50mg

Dasatinib- In accordance with NICE guidance

Not recommended for chronic myeloid leukaemia (first line) (TA251)

Erlotinib

Tablets 25mg, 100mg, 150mg

Erlotinib- In accordance with NICE guidance

A recommended first line option in locally advanced or metastatic non-small-cell lung cancer (EGFR-TK mutation positive) (TA258)

Barnet and Chase Farm hospitals

Everolimus

Tablets 5mg, 10mg

Everolimus- In accordance with NICE guidance

Not recommended for second-line treatment of advanced renal cell carcinoma (TA219)

Not recommended in combination with exemestane, for treating postmenopausal women with advanced human epidermal growth factor receptor 2 (HER2) negative hormone-receptor-positive breast cancer that has recurred or progressed following treatment with a non-steroidal aromatase inhibitor. (TA295)

Gefitinib

Tablets 250mg

Imatinib

Tablets 100 mg, 400 mg

For consultant haematologist use only

Imatinib- In accordance with NICE guidance

Recommended as an option for chronic phase Philadelphia-chromosome-positive CML (first line) (TA251)

Nilotinib

Capsules 150mg, 200mg

Nilotinib- In accordance with NICE guidance

Recommended for Philadelphia-chromosome-positive CML only under a patient access scheme (TA251)

Ruxolitinib

Tablets 5mg, 15mg, 20mg

Treatment not recommended by NICE. Applications via CDF on individual basis.

Vemurafenib

Tablets 240mg

Vemurafenib- In accordance with NICE guidance

Recommended as an option for treating BRAF V600 mutation positive unresectable or metastatic melanoma only if the manufacturer provides the discount agreed in the patient access scheme (TA269)

Barnet and Chase Farm hospitals

Taxanes

Cabazitaxel

Injection 60mg in 1.5mL

Cabazitaxel- In accordance with NICE guidance

Not recommended for patients with hormone refractory, metastatic prostate cancer who have had docetaxel (TA255)

Docetaxel

Injection 20mg, 80mg, 140mg

In line with NICE guidance

Paclitaxel

Injection 30mg in 5mL, 150mg in 25mL, 300mg in 50mL

In line with NICE guidance

Trastuzumab

Infusion 150 mg

Trastuzumab- In accordance with NICE guidance

Not recommended with an aromatase inhibitor for post-menopausal women with HER2 and hormone receptor positive metastatic breast cancer (TA257)

8.2 Drugs affecting the immune response

8.2.1 Antiproliferative immunosuppressants

Azathioprine

Tablets 25 mg, 50 mg

Injection 50 mg vial

Mycophenolate Mofetil

Capsules 250mg

Tablets 500mg

Liquid 1g in 5mL

8.2.2 Corticosteroids and other immunosuppressants

Ciclosporin (Cyclosporin)

Capsules 25 mg, 50 mg, 100 mg

(Capimune[®])

Oral solution 100 mg in 1 mL

(Neoral[®])

Concentrate 50 mg in 1 mL, 250 mg in 5 mL

(For intravenous infusion - oily)

(Sandimmun[®])

Barnet and Chase Farm hospitals

Tacrolimus

Capsules 500 micrograms, 1mg, 5mg

8.2.3 Anti-lymphocyte monoclonal antibodies

Alemtuzumab

(For Haematologists use only in accordance with NICE guidance)

Injection, 30mg in 1mL

Concentrate for intravenous infusion

Rituximab

(For Haematologists use only in accordance with NICE guidelines)

Injection, 100 mg in 10 mL, 500 mg in 50 mL

Concentrate for intravenous infusion

Rituximab- In accordance with NICE guidance

Recommended in combination for first line treatment of stage III-IV follicular lymphoma (TA243)

Recommended as a possible treatment to maintain remission in follicular non-Hodgkin's lymphoma (TA226)

Rituximab (for ITP)

Recommended for refractory or relapsed disease only, by North Central London JFC

8.2.4 Other immunomodulating drugs

Interferon alfa

Intron A[®]

Injection pen 15 (18) million units in 1 (1.2) mL,

50 (60) million units in 1 (1.2) mL

Note: Each 1.5 mL multidose cartridge delivers 6 doses of 0.2 mL, i.e. a total of 1.2 mL

Roferon[®]

Prefilled syringe 3 mega-units in 0.5mL, 4.5 mega-units in 0.5mL,

6 mega-units in 0.5mL, 9 mega-units in 0.5mL

Cartridge

18mega-units in 0.6mL cartridge

Roferon[®] pen device

Barnet and Chase Farm hospitals

Peginterferon Alfa

In line with NICE guidance

Pegasys[®] (pen or prefilled syringe) 135micrograms, 180 micrograms

ViraferonPeg[®] (pen) 50 micrograms, 80 micrograms, 100 micrograms,
120 micrograms, 150 micrograms

Interferon Beta

Avonex[®] 30 micrograms

Rebif[®] 22 micrograms, 44 micrograms

Betaferon[®] 300 micrograms

BCG bladder instillations

Immucyst[®] 81mg vial

Oncotice[®] 12.5mg vial

Fingolimod

Capsules 500 micrograms

Fingolimod- In accordance with NICE guidance

Recommended for patients not responding sufficiently to beta interferon (TA254)

Glatiramer Acetate

Injections 20 mg in 1 mL

In line with NICE guidance TA32

Lenolidomide

Capsules 5mg, 10mg, 15mg, 25mg

Thalidomide

Capsules 50mg

Tablets 50mg, 100mg

Thalidomide- In accordance with NICE guidance

A recommended option for specified people with multiple myeloma (first line) (TA228)

Natalizumab

Infusion 300mg in 15mL

In line with NICE guidance TA127

Teriflunomide

Tablets 14mg

Teriflunomide- In accordance with NICE guidance

Recommended as a treatment option for adults with active relapsing-remitting multiple sclerosis (not highly active or rapidly evolving) (TA303)

Barnet and Chase Farm hospitals

8.3 Sex hormones and hormone antagonists in malignant disease

8.3.1 Oestrogens

Diethylestilbestrol (Stilboestrol)

Tablets 1 mg, 5mg

8.3.2 Progestogens

Medroxyprogesterone

Tablets 100 mg, 200 mg, 400mg
(see also 6.2.1.2 for other strengths)

Megestrol Acetate

Tablets 160 mg

Norethisterone

See section 6.4.1. 2

8.3.4 Hormone antagonists

8.3.4.1 Breast cancer

Tamoxifen

Tablets 10 mg, 20 mg
Oral solution 10 mg in 5 mL

Anastrozole

Tablets 1 mg

Exemestane

Tablets 25 mg

In line with NICE guidance TA112

Letrozole

Tablets 2.5 mg

Approved for the treatment of steroid positive breast cancer in post-menopausal women

Toremifene

Tablets 60mg

8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists

Gonadorelin analogues

Goserelin

Implant 3.6 mg, 10.8mg

Leuprorelin

Injection 3.75 mg, 11.25 mg

Triptorelin

Injection 3mg, 3.75mg, 11.25mg

Barnet and Chase Farm hospitals

Anti-androgens

Abiraterone

Tablets 250mg

Abiraterone- In accordance with NICE guidance

A recommended option for metastatic (castration resistant) prostate cancer after testosterone reduction therapy and docetaxel (TA259)

Bicalutamide

Tablets 50 mg, 150 mg

Cyproterone acetate

Tablets 50 mg, 100 mg

Gonadotrophin-releasing hormone antagonists

Degarelix

Injection 80mg vial, 120mg vial

Degarelix (for advanced prostate cancer)

Recommended as an option for use in patients unable to tolerate other treatments **ONLY**, by North Central London JFC

8.3.4.3 Somatostatin analogues

Octreotide

Injection 50 micrograms in 1mL, 100 micrograms in 1 mL,
 500 micrograms in 1mL

Depot injection 20mg, 30mg

Octreotide (for hyperinsulinaemic hypoglycemia)

Recommended for post bariatric use, by North Central London JFC

Prescribing at BCFH should be continuation of prescribing, initiation must be by bariatric centres ONLY

Chapter 9
Nutrition and blood

9 Nutrition and blood

9.1 Anaemias and some other blood disorders

9.1.1 Iron-deficiency anaemias

9.1.1.1 Oral iron

Iron contents of different iron salts

Iron salt	Amount	Content of ferrous Iron (elemental iron)
Ferrous fumarate	200 mg	65 mg
Ferrous gluconate	300 mg	35 mg
Ferrous succinate	100 mg	35 mg
Ferrous sulphate	300 mg	60 mg
Ferrous sulphate, dried	200 mg	65 mg

Modified release preparations are designed to release iron gradually so that a smaller amount of iron is present in the lumen at any one time. However, modified-release preparations are likely to carry iron past the first part of the duodenum into an area of the gut where iron absorption may be poor. The low incidence of side-effects may reflect the small amounts of iron available for absorption under these conditions and so the preparations have no therapeutic advantage and should not be used.

Ferrous Sulphate

Tablets, dried	200 mg	(≡ 65 mg iron)
Filmtabs (modified released)	325 mg	(≡ 105 mg iron)

(Ferrograd[®])

Ferrous Fumarate

Syrup	140 mg in 5 mL	(≡ 45 mg iron per 5 mL)
-------	----------------	-------------------------

(Fersamal[®])

Tablets	210mg	
---------	-------	--

Ferrous Gluconate

Tablets	300 mg	(≡ 35 g iron)
---------	--------	---------------

Sodium Feredetate

Elixir, sugar free	190 mg in 5 mL	(≡ 27.5 mg iron per 5 mL)
--------------------	----------------	---------------------------

(Sytron[®])

Iron and folic acid

Pregaday [®] tablets	Ferrous fumarate (≡ 100 mg iron) and Folic acid 350 micrograms
-------------------------------	---

9.1.1.2 Parenteral iron

Iron Sucrose

Injection (Venofer [®])	100 mg in 5 mL
-----------------------------------	----------------

Iron Isomaltoside 1000

Injection (Monofer [®])	100mg in 1mL, 500mg in 5mL
-----------------------------------	----------------------------

Approved for use in view of better tolerability and capacity benefit

Barnet and Chase Farm hospitals

9.1.2 **Drugs used in megaloblastic anaemias**

Hydroxocobalamin

Injection 1 mg in 1 mL

Cyanocobalamin

Tablets 50 micrograms

Prevention of Neural Tube effects:

- a) To **prevent neural tube defect in high risk women (including those with previous pregnancies affected by neural tube defects)**: Folic Acid 5mg once daily. Supplementation to continue until week 12 of pregnancy
- b) To **prevent neural tube defect in low risk women**: For women who are planning pregnancy, Folic Acid 400 mcg daily before conception and during the first 12 weeks of pregnancy. Women who suspect they are pregnant should start at once and continue until week 12 of pregnancy.

Folic Acid

Tablets 400 micrograms, 5 mg

Syrup 400 micrograms in 5mL, 2.5 mg in 5 mL

9.1.3 **Drugs used in hypoplastic, haemolytic, and renal anaemias**

Erythropoietins

Epoetin alfa (Binocrit®)

Prefilled syringe 1000 units, 2000 units, 3000 units, 4000 units,
5000 units, 6000 units, 8000 units, 10 000 units,
20 000 units, 40 000 units

Epoetin alfa (Binocrit) (for anaemia in patients treated for hepatitis C)
Recommended as an option for use in patients treated for hepatitis C, with anaemia (Hb levels $\leq 10\text{g/dL}$), by North Central London JFC

Epoetin beta (Neorecormin®)

Prefilled syringe 500 units, 2000 units, 3000 units, 4000 units,
5000 units, 6000 units, 10 000 units, 20 000 units,
30 000 units

Methoxy Polyethylene Glycol-epoetin Beta (Mircera®)

Prefilled syringe 50 micrograms in 0.3mL

Iron overload

Deferasirox

Dispersible tablets 125 mg, 250 mg, 500mg

Approved for restricted use. Exceptional funding will be applied for all cases

Deferiprone

Tablets 500mg

Desferrioxamine Mesilate

Injection 500 mg, 2 g

(Desferal®)

Barnet and Chase Farm hospitals

9.1.4 **Drugs used in platelet disorders**

Eltrombopag

Tablet 25mg, 50mg

Eltrombopag (for ITP)
 Recommended for patients with ITP after splenectomy and use of IVIG, by North Central London JFC

Eltrombopag- In accordance with NICE guidance
 Recommended for specific people with chronic, severe, and refractory ITP (TA293)

Romiplostim

Injection 250 micrograms

Romiplostim (for ITP)
 Recommended for patients with ITP after splenectomy, use of IVIG and Eltrombopag, by North Central London JFC

Romiplostim- In accordance with NICE guidance
 Recommended for specific people with chronic, severe, and refractory ITP (TA221)

Anagrelide

Capsules 500 micrograms

2nd line treatment for the reduction of elevated platelet counts in patients at risk of essential thrombocythaemia. Prescribing restricted to consultant haematologists only

9.1.6 **Drugs used in neutropenia**

Filgrastim

Injection 30 million units (300 micrograms) in 0.5mL
 48 million units (480 micrograms) in 0.5mL

Lenograstim

Injection 13.4 million-unit (105 micrograms)
 33.6 million-unit (263 micrograms)

Pegfilgrastim

Injection 0.6 mL (6 mg) prefilled syringe

Barnet and Chase Farm hospitals

9.2 Fluids and electrolytes

9.2.1 Oral preparations for fluid and electrolyte imbalance

9.2.1.1 Oral potassium

Potassium Chloride

Syrup (Kay-Cee-L[®])	1 mmol each of K ⁺ and Cl ⁻ in 1 mL
Tablets, effervescent (Sando-K[®])	12 mmol K ⁺ and 8 mmol Cl ⁻ per tablet
Tablets, modified release (Slow-K[®])	8 mmol each of K ⁺ and Cl ⁻ per tablet

Potassium removal

Polystyrene sulphonate resins

Calcium polystyrene sulphonate

Powder (Calcium Resonium[®])	300 g tub
--	-----------

Sodium polystyrene sulphonate

Powder (Resonium-A[®])	454 g tub
--	-----------

9.2.1.2 Oral sodium and water

Sodium chloride

Tablets, modified released (Slow Sodium[®])	600 mg (approx. 10 mmol each of K ⁺ and Cl ⁻ per tablet)
--	--

Oral rehydration therapy (ORT)

Oral Hydration Salts (ORS)

Oral powder	one sachet reconstituted with 200 mL water will provide Na ⁺ 12 mmol, K ⁺ 4 mmol, Cl ⁻ 12 mmol, citrate 2 mmol, and glucose 18 mmol
<i>(Five sachets reconstituted with 1 litre of water provide Na⁺ 60 mmol, 25mmol K⁺ mmol, Cl⁻ 60 mmol, citrate 10 mmol, and glucose 90 mmol)</i>	

9.2.1.3 Oral bicarbonate

Sodium Bicarbonate

Capsules	500 mg
----------	--------

Potassium bicarbonate

Tablets, effervescent	6.5 mmol K ⁺ per tablet
-----------------------	------------------------------------

Barnet and Chase Farm hospitals

9.2.2 Parenteral preparations for fluid and electrolyte imbalance

9.2.2.1 Electrolytes and water

Intravenous sodium

Sodium Chloride

	Strength	Pack Size
Intravenous Injection	0.9% (9g, 150 mmol each Na ⁺ and Cl ⁻ / litre)	2 mL, 5 mL, 10 mL, 20mL amps, 50mL vial
Intravenous Infusion	0.9% (9g, 150 mmol each Na ⁺ and Cl ⁻ / litre)	50 mL, 100 mL, 250 mL, 500 mL, 1000 mL
Intravenous infusion	2.7%	500 mL
Intravenous Injection (For Paediatric use only)	30%	10 mL
Bladder irrigation	0.9%	1 L, 3 L
Polyfusor	0.18%, 0.45%, 1.8%	500 mL 500 mL 500 mL
Sachets for irrigation	0.9%	25 mL

Sodium Chloride and Glucose

	Strength	Pack Size
Intravenous infusion	0.18% (1.8g, 30 mmol each Na ⁺ and Cl ⁻) NaCl & 4% anhydrous glucose	500 mL, 1000 mL
Intravenous infusion	0.18% NaCl & 10% anhydrous glucose	500 mL
Intravenous infusion	0.45% NaCl & 5% glucose	500 mL
Intravenous infusion	0.45% NaCl & 2.5% glucose (For Paediatric use only)	500 mL
Intravenous infusion	0.9% NaCl & 5% glucose	500 mL
Intravenous infusion	0.9% NaCl & 10% glucose	500 mL

Sodium lactate, Compound

(Hartmann's Solution; Ringer-lactate Solution for Injection)

	Contents	Pack Size
Intravenous infusion	Sodium chloride 0.6%, sodium lactate 0.25%, potassium chloride 0.04%, calcium chloride 0.027%	500 mL, 1000 mL

Intravenous glucose

Glucose

	Strength	Pack Size
Intravenous infusion	5%	50 mL, 100 mL, 250 mL, 500 mL, 1000 mL
Intravenous infusion	10%	500 mL, 1000mL
Intravenous infusion	15%	500 mL
Intravenous infusion	20%	500 mL
Intravenous infusion	40%	500 mL
Intravenous infusion	50%	20mL, 50mL, 500 mL
Injection in syringe (Min-I-Jet Glucose®)	50%	50 mL

Barnet and Chase Farm hospitals

Intravenous potassium

Potassium Chloride 0.15% and Glucose 5%

Intravenous Infusion 20 mmol K⁺ in 1000 mL

Potassium Chloride 0.3% and Glucose 5%

Intravenous Infusion 20 mmol K⁺ in 500 mL
40 mmol K⁺ in 1000 mL

Potassium Chloride 0.15% and Sodium Chloride 0.9%

Intravenous Infusion 10 mmol K⁺ in 500 mL
20 mmol K⁺ in 1000 mL

Potassium Chloride 0.3% and Sodium Chloride 0.9%

Intravenous Infusion 20 mmol K⁺ in 500 mL
40 mmol K⁺ in 1000 mL

Potassium Chloride 0.6%, Sodium Chloride 0.9%

Intravenous Infusion 40 mmol K⁺ in 500 mL

Potassium Chloride 0.15%, Sodium Chloride 0.18% and Glucose 4%

Intravenous Infusion 10 mmol K⁺ in 500 mL
20 mmol K⁺ in 1000 mL

Potassium Chloride 0.3%, Sodium Chloride 0.18% and Glucose 4%

Intravenous Infusion 20 mmol K⁺ in 500 mL
40 mmol K⁺ in 1000 mL

Potassium Chloride, Concentrate, Sterile

Sterile concentrate 15% in 10 mL amp
(150 mg, 2 mmol each of K⁺ and Cl⁻/mL)

Must be diluted with NOT LESS than 50 times its volume of sodium chloride intravenous infusion 0.9% or other suitable diluent and MIXED WELL

Bicarbonate and lactate

Sodium Bicarbonate

	Strength	Pack Size
Polyfusor	1.26%	500 mL
Polyfusor	4.2%	500 mL
Polyfusor	8.4%	200mL
Intravenous Infusion	8.4%	10mL, 100mL
Intravenous Injection (Min-I-Jet)	4.2%,	10 mL
Intravenous Injection (Min-I-Jet)	8.4%,	50 mL

Barnet and Chase Farm hospitals

Water

	Pack Size
Water for Injections	5 mL, 10 mL, 20 mL, 100 mL
Inhalation pack	1 L
Irrigation bags	1 L, 3 L
Purified Water	5 L
Sterile Water	1 L bottle
Sachets for irrigation	100mL

Dialysis Fluids

Haemofiltration Solution

Prismasol[®] 4 5000 mL

9.3.2.2 Plasma and plasma substitutes

Albumin Solution

Human Albumin Solution 4.5%, 20%

Gelatin (Gelaspan[®]) (replacing Volplex)

Intravenous infusion 500 mL

Electrolyte solution (Plasmalyte[®] 148)

Intravenous infusion 1000mL

For use in ITU, HDU, and theatres, on both sites.

9.5 Minerals

9.5.1 Calcium and Magnesium

9.5.1.1 Calcium Supplements

Calcium Chloride

Chewable tablets (Adcal[®]) 1.5g (Ca²⁺ 15 mmol)

Calcium Gluconate

Effervescent tablets 1 g (Ca²⁺ 2.25 mmol and Na⁺ 4.46 mmol)

Calcium Lactate

Tablets 300mg (Ca²⁺ 1 mmol)

Calcium-Sandoz[®]

Syrup 300 mL (calcium 108.3 mg or Ca²⁺2.7 mmol) in 5 mL)

Sandocal[®]-1000

Tablets, effervescent 1 g (Ca²⁺ 25 mmol)

Calcium Gluconate

Injection 10%

Calcium Chloride

Injection 10mmol in 10mL (50mL vial), 13.4% (10mL amp)

Injection 10%

Barnet and Chase Farm hospitals

(Min-I-Jet[®])

9.5.1.2 Hypercalcaemia and hypercalciuria

Bisphosphonates

See section 6.6.2

Corticosteroids

See section 6.3

Calcitonin

See section 6.6.1

9.5.1.3 Magnesium

Magnesium Sulphate

Injection

50% (2 mmol Mg²⁺/mL), 2mL and 10 mL amp

Minijet

50% 4mL

9.5.2 Phosphorus

9.5.2.1 Phosphate supplements

Phosphate

Tablets, effervescent

16.1mmol phosphate, 20.4mmol Na⁺,
3.1mmol K⁺ per tablet

Phosphates polyfusor

500mL

9.5.2.2 Phosphate-binding agents

Calcium Salts

Adcal[®]

See section 9.5.1.1

Lanthanum

Chewable tablets

500mg, 750mg, 1000mg

Granules

1000mg

9.5.3 Fluoride

Fluoride

Mouthwash (**Fluorigard[®]**)

0.05%

9.5.4 Zinc

Zinc

Tablets, effervescent (**Solvazinc[®]**) zinc sulphate monohydrate 125mg (≡ 45 mg Zn)

Capsules (**Zincomed[®]**)

220 mg

Injection

50 micromols in 1mL

Barnet and Chase Farm hospitals

9.6 Vitamins

9.6.1 Vitamin A

Vitamin A and D

Capsules

9.6.2 Vitamin B group

Thiamine (Vitamin B₁)

Tablets 50 mg, 100 mg

Vitamins B and C (Pabrinex[®])

*Intravenous injections should be administered slowly (over 10 mins) to minimize risk of potentially **serious anaphylactic reaction***

High potency, 10 mL (one pair)

Intravenous Injection

High potency, 10 mL (one pair)

Intramuscular Injection

Pyridoxine Hydrochloride (Vitamin B₆)

Tablets 10 mg, 20 mg, 50 mg

Injection 100mg in 2mL

Oral vitamin B complex preparations

Vitamin B, Compound, Strong

Tablets

9.6.3 Vitamin C (Ascorbic Acid)

Ascorbic Acid

Tablets 50 mg, 100 mg, 200 mg, 500 mg

Tablets, effervescent 1 g

Injection 500mg in 5mL

9.6.4 Vitamin D

Note: Vitamin D prescribing policy is on Trust Intranet (November 2010)

Ergocalciferol

Injection 7.5mg in 1mL (300 000 units)

Calcium and Ergocalciferol

Tablets 97 mg calcium, 400 units ergocalciferol

Alfacalcidol (1 α -Hydroxycholecalciferol)

Capsules 250 nanograms, 500 nanograms, 1 microgram

Barnet and Chase Farm hospitals

(**AlfaD**[®] Capsules contain arachis (peanut oil) and **One-Alpha**[®] Capsules contain sesame oil)

Oral drops, sugar-free 2 micrograms in mL (1 drop contains 100 nanograms)
Injection 2 micrograms in 1mL

Calcitriol (1, 25-Dihydroxycholecalciferol)

Capsules 250 nanograms, 500 nanograms
(**Rocaltrol**[®])

Colecalciferol (cholecalciferol, Vitamin D₃)

Capsules (**Fultinum D3**[®]) 20 micrograms (800 units)
Capsules (**Pro D3**[®]) 400 units, 1000 units, 2000 units, 3000 units,
10 000 units
Drops (**Pro D3**[®]) 400 units
Liquid (**Pro D3**[®]) 2000 units in 1mL, 3000 units in 1mL

Colecalciferol with calcium

Adcal D3[®] (replaces *Calcichew*)

Tablets (chewable) 1.5g calcium, 400 units colecalciferol
Dissolve 1.5g calcium, 400 units colecalciferol
Caplet 750 mg calcium, 200 units colecalciferol

9.6.5 **Vitamin E (Tocopheryl)**

Alpha Tocopheryl Acetate

Capsules (**Vita E Gels**[®]) 200 international units, 400 international units

Tocopheryl Acetate

Liquid 100mg in 1mL

9.6.6 **Vitamin K**

Menadiol sodium phosphate

Tablets 10 mg

Phytomenadione (Vitamin K₁)

Capsules 1mg

Colloidal formulation

Injection 2mg in 0.2 mL

(**Konakion**[®] **MM Paediatric**)

This can be administered by mouth or by intramuscular injection or intravenous injection.

Injection 10 mg in 1 mL

(**Konakion**[®] **MM**)

May be administered by slow IV injection or by IV infusion in glucose 5%;

NOT for IM use

Barnet and Chase Farm hospitals

9.6.7 Multivitamin preparations

Tablets

Oral Drops 50mL

(Dalivit[®])

Ketovite[®]

(For prevention of deficiency in disorders of carbohydrate or amino acid metabolism)

Tablets

Liquid

9.8 Metabolic disorders

9.8.1 Drugs used in metabolic disorders

Wilson's disease

Penicillamine See section 10.1.3

Carnitine deficiency

Carnitine

(For the management of primary carnitine deficiency due to inborn errors of metabolism or of secondary deficiency in haemodialysis patients)

Paediatric oral solution 30%

Injection 200mg in 1mL

Chewable tablets 1g

Urea cycle disorders

Sodium Phenylbutyrate

Liquid 1g in 5mL

Chapter 10

Musculoskeletal and joint diseases

10 Musculoskeletal and joint diseases

10.1 Drugs used in rheumatic diseases and gout

Sodium hyaluronate injections – Non-formulary

All synthetic synovial fluid analogues have been **removed from the Trust formulary**, as it has been agreed by the BCFH D&T panel that the evidence for these products is not strong enough and that cost effectiveness has not been demonstrated in its use in rheumatology patients.

Not recommended for knee osteoarthritis, by North Central London JFC

10.1.1 Non-steroidal anti-inflammatory drugs

Naproxen is the oral NSAID of choice for the Trust

Ibuprofen

Tablets	200 mg, 400 mg, 600 mg
Suspension	100 mg in 5 mL
Modified release tablets	800 mg
Orodispersible tablets	200mg (<i>restricted to DSU only</i>)

Diclofenac sodium

Tablets	25 mg, 50 mg
Dispersible tablets	50 mg
Modified release tablets	75 mg, 100 mg
<i>Diclofenac oral formulations are restricted for use only in patients that are intolerant to Naproxen, or patients already on Diclofenac on admission</i>	
Suppositories	12.5 mg, 25 mg, 50 mg, 100 mg
Injection	37.5mg in 1 mL

Diclofenac sodium with misoprostol

Arthrotec 50[®] tablets	Diclofenac sodium 50 mg, Misoprostol 200 micrograms
Arthrotec 75[®] tablets	Diclofenac sodium 75 mg, Misoprostol 200 micrograms

Etodolac

Modified release tablets	600 mg
--------------------------	--------

Etoricoxib

Tablets	30mg, 60mg, 90mg, 120mg
---------	-------------------------

Fenoprofen

Tablets	600mg
---------	-------

Barnet and Chase Farm hospitals

Flurbiprofen

Tablets	50mg, 100mg
Slow release capsules	200mg

Indometacin (Indomethacin)

Capsules	25 mg, 50 mg
Modified release capsules	75 mg
Suppositories	100 mg

Ketoprofen

Capsules	50 mg
Modified release capsules	100 mg

Mefenamic Acid

Capsules	250 mg
Tablets	500 mg

Meloxicam

Tablets	7.5 mg, 15 mg
---------	---------------

Nabumetone

Tablets	500 mg
---------	--------

Naproxen

Naproxen is the oral NSAID of choice for the Trust

Tablets	250 mg
Enteric coated tablets	250 mg, 500 mg

Naproxen and Misoprostol

Tablets (Naprotec [®])	500mg/200mg
----------------------------------	-------------

Piroxicam

Capsules	10 mg, 20 mg
----------	--------------

Sulindac

Tablets	100 mg, 200 mg
---------	----------------

Aspirin and the salicylates

<u>Aspirin</u>	See section 4.7.1
-----------------------	-------------------

10.1.2 Corticosteroids

10.1.2.1 Systemic corticosteroids

See section 6.3

10.1.2.2 Local corticosteroid injections

Dexamethasone sodium phosphate

Injection	8 mg in 2 mL
-----------	--------------

Hydrocortisone acetate

Injection	25 mg in 1 mL
-----------	---------------

Methylprednisolone acetate

Injection	40 mg in 1 mL, 80 mg in 2mL, 120mg in 3mL
-----------	---

Barnet and Chase Farm hospitals

Methylprednisolone acetate and lidocaine

Injection methylprednisolone 40 mg, lidocaine 10mg; in 1mL

Prednisolone acetate

Injection 25 mg in 1 mL

Triamcinolone acetonide

Injection (**Adcortyl**[®]) 10 mg in 1 mL

(For Intra-articular / Intradermal use only)

Injection (**Kenalog**[®]) 40 mg in 1 mL

(For Intra-articular / Intramuscular use only)

10.1.3

Drugs that suppress the rheumatic disease process

Sodium Aurothiomalate

Injection 10 mg in 0.5 mL, 20 mg in 0.5 mL,
50 mg in 0.5 mL

Penicillamine

Tablets 125mg, 250 mg

Hydroxychloroquine Sulphate

Tablets 200 mg

Azathioprine see section 8.2.1

Ciclosporin see section 8.2.2

Leflunomide

Tablets 10 mg, 20 mg, 100 mg

Methotrexate

Tablets 2.5 mg

Injection see section 8.1.3

Cytokine modulators

Abatacept

Injections 250mg

Abatacept - In accordance with NICE guidance

A recommended option (in combination with methotrexate) for treating RA in adults whose disease has responded inadequately to 2 DMARDS inc methotrexate (TA280)

Adalimumab

Injections 40 mg

In line with NICE guidance TA130, TA143 & TA199

Certolizumab pegol

Pre-filled syringe 200 mg

In line with NICE guidance TA186

Etanercept

Injections 25 mg, 50mg

In line with NICE guidance TA130, TA143 & TA199

Barnet and Chase Farm hospitals

Golimumab

Injections 50mg

Golimumab - In accordance with NICE guidance

A recommended option for severe, active ankylosing spondylitis in the same circumstances as TA143 when NSAIDs unsuccessful (TA233)

A recommended option (in the same circumstances as TA130) for RA after other specified treatments have failed or not been tolerated (TA225)

Recommended as a possible treatment for psoriatic arthritis after trying other DMARDs in the same circumstances as TA199 (TA2200)

Unable to recommend for methotrexate-naïve RA due to lack of evidence submission (TA224)

Infliximab

Injections 100 mg

In line with NICE guidance TA130, TA143 & TA199

Rituximab

Injection 100mg in 10mL, 500mg in 50mL

In line with NICE guidance TA195

Tocilizumab

Injections 20mg/1mL (4mL, 10mL, 20mL vials)

Tocilizumab - In accordance with NICE guidance

(With methotrexate) A recommended option (in the same circumstances as TA130) after other specified treatments have failed or not been tolerated (TA247)

Recommended for juvenile idiopathic systemic arthritis if NSAIDs, steroids and methotrexate have failed (TA237)

Sulfasalazine

Tablets 500 mg

Enteric coated tablets 500 mg

N.B. SEE SECTION 6.6 FOR DRUGS AFFECTING BONE METABOLISM

Barnet and Chase Farm hospitals

10.1.4 Gout and cytotoxic-induced hyperuricaemia

Acute attacks of gout

Colchicine

Tablets 500 micrograms

Long-term control of gout

Allopurinol

Tablets 100 mg, 300 mg

Febuxostat

Tablets 80mg, 120mg

In line with NICE guidance TA164

Sulfinpyrazone

Tablets 100 mg

Hyperuricaemia associated with cytotoxic drugs

Rasburicase

Infusion 1.5 mg, 7.5mg

In line with NICE guidance

Rasburicase (for tumour lysis syndrome in adults)
Restricted for patient intolerant of allopurinol by North Central London JFC

10.2 Drugs used in neuromuscular transmission

10.2.1 Drugs which enhance neuromuscular transmission

Anticholinesterases

Neostigmine

Tablets 15 mg

Injection 2.5 mg in 1 mL

Pyridostigmine bromide

Tablets 60 mg

Fampridine

Tablets 10mg

Approved for Dr Wilson to use in MS patients only - subject to funding

10.2.2 Skeletal muscle relaxants

Baclofen

Tablets 10 mg

Liquid 5 mg in 5 mL

Injection 10mg in 5mL

Dantrolene sodium

Capsules 25 mg, 100 mg

Diazepam

See section 4.1.2

Barnet and Chase Farm hospitals

Tizanidine

Tablets 2 mg, 4 mg

Approved for treatment of spasticity in patients unable to tolerate either baclofen or gabapentin

Cannabis extract oromucosal spray (**Sativex[®]**) – non-formulary

Sativex was **not approved** for use by BCFH D&T panel, due to insufficient evidence of cost effectiveness

Nocturnal leg cramps

Quinine sulphate

see section 5.4.1

10.3

Drugs for the relief of soft-tissue disorders and topical pain relief

10.3.1

Enzymes

Hyaluronidase

Injection 1500-unit amp

10.3.2

Rubefacients, topical NSAIDS, capsaicin and poultices

Topical NSAIDS and counter-irritants

Ibuprofen

Gel ibuprofen 5%

Feldene[®]

Gel piroxicam 0.5%

MoveLat[®]

Cream mucopolysaccharide polysulphate 0.2%, salicylic acid 2%, thymol 0.1%

Traxam[®]

Gel felbinac 3%

Voltarol Emulgel[®]

Gel diclofenac diethylammonium salt 1.16%
(Equivalent to diclofenac sodium 1%)

Capsaicin

Cream 0.025%, 0.075%

Transvasin[®] Heat Rub

Cream tetrahydrofurfuryl salicylate 14%, ethyl hexyl nicotinate 2%

Chapter 11

Eye

11 **Eye**

For eye drops, eye ointment, intravitreal and intracameral injections and intravitreal implants, see the Moorfields Eye Hospital formulary

<http://www.moorfields.nhs.uk/Publicationsandresources/Medicines>

Barnet and Chase Farm hospitals

Chapter 12

Ear, nose, and oropharynx

12 Ear, nose and oropharynx

12.1 Drugs acting on the ear

12.1.1 Otitis externa

Anti-inflammatory preparations

Betamethasone Sodium Phosphate

Drops (for ear, eye, or nose) see section 11.4.1

Betamethasone with antibacterial

Drops (for ear, eye, or nose) see section 11.4.1

Dexamethasone with antibacterial

Ear spray
(**Otomize[®]**) Dexamethasone 0.1%,
Neomycin sulphate 3250 units/1 mL,
Glacial acetic acid 2%

Drops (for ear or eye)
(**Sofradex[®]**) Dexamethasone 0.05%,
Framycetin sulphate 0.5%,
Gramicidin 0.005%

Flumetasone Pivalate with antibacterial

Ear drops
(**Locorten-Vioform[®]**) Flumetasone pivalate 0.02%,
Clioquinol 1%

Hydrocortisone with antibacterial

Ear drops
(**Gentisone-HC[®]**) Hydrocortisone acetate 1%,
Gentamicin sulphate 0.3%

Prednisolone Sodium Phosphate

Drops (for ear or eye) see section 11.4.1

Anti-infective preparations

Chloramphenicol

Ear drops 5%

Clotrimazole

Solution 1%

Gentamicin

Drops (for ear or eye) see section 11.4.3

Barnet and Chase Farm hospitals

12.1.3	Removal of ear wax	
	<u>Olive Oil</u>	
	Ear drops	
	<u>Sodium bicarbonate</u>	
	Ear drops	5%
12.2	Drugs acting on the nose	
12.2.1	Drugs used in nasal allergy	
	Corticosteroids	
	<u>Beclometasone dipropionate</u>	
	Nasal spray	50 micrograms / metered dose
	<u>Betamethasone sodium phosphate</u>	
	Drops (for ear, eye, or nose)	see section 11.4.1
	<u>Budesonide</u>	
	Nasal spray	64 micrograms/ metered spray
	(Rhinocort Aqua [®])	
	<u>Fluticasone propionate</u>	
	Aqueous nasal spray	50 micrograms/ metered spray
	(Flixonase [®])	
	Nasal drops (Flixonase [®] nasules)	400 micrograms per dose
	<u>Flunisolide</u>	
	Nasal spray	25 micrograms / metered spray
	<u>Mometasone Furoate</u>	
	Aqueous nasal spray	50 micrograms/metered spray
	Cromoglicate	
	<u>Sodium cromoglicate</u>	
	Aqueous nasal spray	4%
12.2.2	Topical nasal decongestants	
	<u>Sodium chloride</u>	
	Nasal drops	0.9%
	Sympathomimetics	
	<u>Ephedrine hydrochloride</u>	
	Nasal drops	0.5%, 1%
	<u>Xylometazoline hydrochloride</u>	
	Nasal drops	0.1%
	Paediatric nasal drops	0.05%
	Nasal spray	0.1%

Barnet and Chase Farm hospitals

12.2.3

Nasal preparations for infection

Betamethasone and Neomycin see section 11.4.1

Nasal staphylococci

Bactroban Nasal[®] ointment Mupirocin 2% in white soft paraffin

Naseptin[®] cream Chlorhexidine hydrochloride 0.1%,
Neomycin sulphate 3250 units/ g

Epistaxis

Bismuth subnitrate and iodoform (B.I.P.P)

Paste 30 g

Impregnated gauze (sterile) 1.25 cm x 100 cm, 2.5 cm x 100 cm,
1.25 cm x 300 cm, 2.5 cm x 300 cm

12.3

Drugs acting on the oropharynx

12.3.1

Drugs for oral ulceration and inflammation

Benzydamine hydrochloride

Oral rinse 0.15%

Spray 0.15%

Carmellose sodium

Orabase[®] Protective paste Carmellose sodium 16.7%,
(Oral paste) Pectin 16.7%,
Gelatin 16.7%

Corticosteroids

Corlan[®] Pellets Hydrocortisone 2.5 mg

Salicylates

Choline Salicylate Dental Gel, BP 8.7%
(**Bonjela**[®])

12.3.2

Oropharyngeal anti-infective drugs

Miconazole

Oral gel 24 mg in 1 mL (20 mg / mL)
(Sugar free)

Nystatin

Oral suspension 100 000 units in 1 mL

12.3.3

Lozenges

Strepsils[®] lozenges amylmetacresol, dichlorobenzyl alcohol

Barnet and Chase Farm hospitals

12.3.4

Mouthwashes, gargles, and dentifrices

Chlorhexidine gluconate

(Corsodyl[®])

Dental gel	1%
Mouthwash	0.2%

Hydrogen peroxide

Mouthwash	6% (20 vol.)
-----------	--------------

Hexetidine

Mouthwash	0.1%
-----------	------

12.3.5

Treatment of dry mouth

Local treatment

Glandosane [®]	Aerosol spray
Saliva artificial [®]	Spray
Saliva Orthana [®]	Lozenges

Systemic treatment

Pilocarpine

Tablets	5 mg
---------	------

Chapter 13

Skin

Pack sizes have been included as a guide to the amount that will be dispensed.

Extemporaneous items can sometimes be prepared. Please contact the Pharmacy before prescribing a new extemporaneous preparation, as facilities are limited.

It will not always be possible to prepare a product immediately and this may result in a long wait for the patient or necessitate their return to collect the item.

13 **Skin**

13.1 **Management of skin conditions**

13.1.1 **Vehicles**

13.1.2 **Suitable quantities for prescribing**

Suitable quantities of dermatological preparations to be prescribed for specific areas of the body are:

	Creams and ointments	Lotions
Face	15 to 30 g	100 mL
Both hands	25 to 50 g	200 mL
Scalp	50 to 100 g	200 mL
Both arms or both legs	100 to 200 g	200 mL
Trunk	400 g	500 mL
Groins and genitalia	15 to 25 g	100 mL

These amounts are usually suitable for an adult for TWICE daily application for ONE week. The recommendations DO NOT apply to corticosteroid preparations – for suitable quantities of corticosteroid preparations see section 13.4

13.2 **Emollient and barrier preparations**

13.2.1 **Emollients**

Emulsifying Ointment, BP	100g, 500 g
Hydrous (oily cream) ointment	30g, 500g
Liquid Paraffin and White Soft	
Paraffin Ointment, NPF	500 g
Paraffin, White Soft, BP	500 g, 30 g
Paraffin, Yellow Soft, BP	15 g

Aveeno[®] cream 100mL

Cetraben[®] Cream 50g, 500g

For patients in whom E45[®] cream has been ineffective

Dermol[®] Cream 500g

Dermol[®] 500 lotion 500mL

Diprobase[®]

Cream 50 g, 500 g

Ointment 50 g

E45[®] Cream 50 g, 500 g

Barnet and Chase Farm hospitals

Epaderm[®]

Cream	500 g
Ointment	500g
Oilatum[®] cream	150g
Unguentum M[®] Cream	50 g, 100 g, 500g

Preparations containing urea

Aquadrate[®] cream	10%; 100g
Balneum[®] cream	5%; 500g
Balneum Plus[®] cream	5%; 100 g, 500 g
<i>Balneum Plus[®] approved as 1st line urea-containing emollient</i>	
Calmurid[®] cream	10%; 100g, 500g
Eucerin[®] cream	5%, 75mL; 10%, 100mL
Eucerin[®] lotion	10%; 100mL
<i>Eucerin[®] approved as 2nd line urea-containing emollient</i>	

13.2.1.1

Emollient bath and shower preparations

Aqueous Cream, BP	100g, 500 g
Aveeno[®] bath oil	250mL
Aveeno[®] colloidal bath additive	10 x 50g
Balneum[®] Bath oil	200mL, 500 mL
Balneum Plus[®] Bath oil	500 mL
Dermol[®] 200 shower gel	200mL
Dermol[®] 600 bath emollient	600mL
E45[®] bath oil	500mL
Emulsiderm[®] liquid	300mL
Hydromol[®] Emollient	
Bath additive	150 mL
Oilatum[®] Emollient Bath additive	250 mL, 300mL
Oilatum Jr[®] Bath additive	600 mL
Oilatum plus[®] Emollient Bath additive	500 mL

13.2.2

Barrier preparations

Cod liver oil cream	50 g
Dimeticone spray	115g
Zinc and Castor Oil Ointment, BP	15 g
Metanium[®] Ointment	30 g
Siopel[®] Cream	dimeticone '1000' 10%, cetrimide 0.3%, arachis (peanut oil), 50 g
Sudocrem[®] (<i>Restricted use</i>)	30 g

13.3

Topical local anaesthetics and antipruritics

Topical antihistamines are not kept as they may cause sensitisation

Barnet and Chase Farm hospitals

Calamine

Aqueous cream	100 mL
Lotion	200 mL

Crotamiton (Eurax®)

Cream	30 g, 100 g
Lotion	100mL

13.4

Topical corticosteroids

Choice of Formulation

FORMULATION	USE
Water-miscible creams	Moist or weeping lesions
Water miscible ointments	Dry, lichenified or scaly lesions
Lotions	Minimal application to a large or hair-bearing area, or for the treatment of exudative lesions
Occlusive polythene/hydrocolloid dressings	Used only under supervision on a short-term basis for very thick skin (e.g. palms and soles)
Inclusion of urea or salicylic acid	Increases the penetration of the corticosteroid

Topical Corticosteroid Potencies: The preparation containing the **least potent** drug at the lowest strength which is effective is the one of choice; dilution should be avoided whenever possible.

Application: Corticosteroid preparations should normally be applied ONCE or TWICE daily. It is not necessary to apply them more frequently

Suitable quantities for corticosteroid preparations to be prescribed for specific areas of the body are:

Location	Creams and Ointments
Face and neck	15 to 30 g
Both hands	15 to 30 g
Scalp	15 to 30 g
Both arms	30 to 60 g
Both legs	100 g
Trunk	100 g
Groins and genitalia	15 to 30 g

Hydrocortisone

Cream	0.5%, 1%, 2.5%
<i>Potency: mild</i>	
Ointment	0.5%, 1%, 2.5%
<i>Potency: mild</i>	
Alphaderm® Cream	hydrocortisone 1%, urea 10%; 30 g
<i>Potency: moderate</i>	
Calmurid HC® Cream	hydrocortisone 1% urea 10%, lactic acid 5%; 30 g
<i>Potency: moderate</i>	
Eurax-Hydrocortisone® Cream	hydrocortisone 0.25%, crotamiton 10%; 30 g
<i>Potency: mild</i>	

Barnet and Chase Farm hospitals

Canestan HC[®] Cream	hydrocortisone 1%, clotrimazole 1%; 30 g
<i>Potency: mild</i>	
Daktakort[®] Cream	hydrocortisone 1%, miconazole nitrate 2%; 30 g
<i>Potency: mild</i>	
Daktakort[®] Ointment	hydrocortisone 1%, miconazole nitrate 2%; 30 g
<i>Potency: mild</i>	
Fuidin H[®] Cream	hydrocortisone acetate 1%, fusidic acid 2%; 30 g
<i>Potency: mild</i>	
Nystaform-HC[®] Cream	hydrocortisone 0.5%, nystatin 100 000 units/g chlorhexidine hydrochloride 1%; 30 g
<i>Potency: mild</i>	
Timodine[®] Cream	hydrocortisone 0.5%, nystatin 100 000 units / g, benzalkonium chloride solution 0.2%, dimeticone '350' 10%; 30 g
<i>Potency: mild</i>	

Hydrocortisone Butyrate

Locoid[®]

Potency: potent

For dermatology use only

Cream	hydrocortisone butyrate 0.1%; 30g
Ointment	hydrocortisone butyrate 0.1%; 30g
Lipocream	hydrocortisone butyrate 0.1%; 30 g
Scalp lotion	hydrocortisone butyrate 0.1% in an aqueous isopropyl alcohol basis; 100 mL

Locoid C[®] Cream	hydrocortisone butyrate 0.1%, chlorquinaldol 3%; 30 g
-----------------------------------	---

Potency: potent

For dermatology use only

Betamethasone Esters

Betnovate[®]

Potency: potent

Cream	betamethasone valerate 0.1%; 30 g, 100 g
Ointment	betamethasone valerate 0.1%; 30 g, 100 g
Scalp application	betamethasone valerate 0.1%; 100 mL

Betnovate-RD[®]

Potency: moderate

Cream	betamethasone valerate 0.025%; 100 g
Ointment	betamethasone valerate 0.025%; 100 g

Bettamousse[®]

Potency: potent

Foam (=scalp application)	betamethasone valerate 0.12%, 100g
---------------------------	------------------------------------

Barnet and Chase Farm hospitals

Diprosone[®]

Potency: potent

Cream betamethasone dipropionate 0.05%; 30 g
Ointment betamethasone dipropionate 0.05%; 30 g

Diprosalic[®]

Potency: potent

Ointment betamethasone dipropionate 0.05%,
salicylic acid 3%; 30 g
Scalp application betamethasone dipropionate 0.05%,
salicylic acid 2% in an alcoholic base; 100 mL

Betnovate-C[®]

Potency: potent

Cream betamethasone valerate 0.1%,
clioquinol 3%; 30 g
Ointment betamethasone valerate 0.1%,
clioquinol 3%; 30 g

Betnovate-N[®]

Potency: potent

Cream betamethasone valerate 0.1%,
neomycin 0.5%; 30 g
Ointment betamethasone valerate 0.1%,
neomycin 0.5%; 30 g

Fucibet[®] Cream

Potency: potent

betamethasone valerate 0.1%,
fusidic acid 2%, 30g, 60g

Lotriderm[®] cream

Potency: potent

betamethasone dipropionate 0.064%,
clotrimazole 1%, 30g

Clobetasol Propionate

Dermovate[®]

Potency: very potent

Cream clobetasol propionate 0.05%; 30 g, 100 g
Ointment clobetasol propionate 0.05%; 30 g, 100 g
Scalp application clobetasol propionate 0.05%; 100mL

Dermovate-NN[®]

Potency: very potent

Cream clobetasol propionate 0.05%, neomycin
sulphate 0.5%, nystatin 100 000 units/g; 30 g

Barnet and Chase Farm hospitals

Ointment	clobetasol propionate 0.05%, neomycin sulphate 0.5%, nystatin 100 000 units/g, in paraffin basis; 30 g
<u>Clobetasone butyrate</u>	
Eumovate[®]	
<i>Potency: moderate</i>	
Cream	clobetasol butyrate 0.05%; 30 g, 100 g
Ointment	clobetasol butyrate 0.05%; 30 g, 100 g
Trimovate[®] cream	
<i>Potency: moderate</i>	
	clobetasone butyrate 0.05%, oxytetracycline 3%, nystatin 100 000 units/g
<u>Diflucortolone valerate</u>	
<i>For Dermatology use only</i>	
Nerisone[®]	
<i>Potency: potent</i>	
Cream	diflucortolone valerate 0.1%; 30 g
Oily cream	diflucortolone valerate 0.1%; 30 g
Nerisone Forte[®]	
<i>Potency: very potent</i>	
Oily cream	diflucortolone valerate 0.3%; 15 g
Ointment	diflucortolone valerate 0.3%; 15 g
<u>Fluocinolone acetonide</u>	
Synalar[®]	
<i>Potency: potent</i>	
Cream	fluocinolone acetonide 0.025%; 30 g
Gel	fluocinolone acetonide 0.025%; 30 g
Ointment	fluocinolone acetonide 0.025%; 30 g
Synalar 1 in 4 Dilution[®]	
<i>Potency: moderate</i>	
Cream	fluocinolone acetonide 0.00625%; 50 g
Ointment	fluocinolone acetonide 0.00625%; 50 g
Synalar 1 in 10 Dilution[®]	
<i>Potency: mild</i>	
Cream	fluocinolone acetonide 0.0025%; 50 g
Synalar C[®]	
<i>Potency: potent</i>	
Cream	fluocinolone acetonide 0.025%, clioquinol 3%; 15 g

Barnet and Chase Farm hospitals

Ointment fluocinolone acetonide 0.025%,
clioquinol 3%; 15 g

Synalar N[®]

Potency: potent

Ointment fluocinolone acetonide 0.025%,
neomycin sulphate 0.5%; 30 g

Flurandrenolone

Haelan[®]

Tape fludrocortide 4 micrograms per sq. cm;
7.5x200cm, 7.5x50cm

Fluocinonide

Metosyn[®]

Potency: potent

Cream fluocinonide 0.05%; 25g

Ointment fluocinonide 0.05%; 25g

Fluticasone propionate

Cutivate[®]

Potency: potent

Cream fluticasone propionate 0.05%, 15g

Ointment fluticasone propionate 0.05%, 15g

Mometasone furoate

Elocon[®]

Potency: potent

For Dermatology use only

Cream mometasone furoate 0.1%; 30 g

Ointment mometasone furoate 0.1%; 30 g

Scalp lotion mometasone furoate 0.1% in an aqueous
isopropyl alcohol basis; 30 mL

Triamcinolone acetonide

Aureocort[®]

Potency: potent

Ointment triamcinolone acetonide 0.1%,
chlortetracycline 3.09% 15g

Tri-Adcortyl[®]

Potency: potent

Cream triamcinolone acetonide 0.1%, gramicidin
0.025%, neomycin sulphate 0.25%, nystatin
100 000 units / g; 30 g

Barnet and Chase Farm hospitals

13.5 Preparations for eczema and psoriasis

13.5.1 Preparations for eczema

Oral retinoid for eczema

Alitretinoin

Capsules (**Toctino**[®]) 10mg, 30mg

In line with NICE guidance TA177

13.5.2 Preparations for psoriasis

Topical preparations for psoriasis

Calcitriol (Silkis[®])

(Restricted to patients who are unable to tolerate Dovonex [Calcipotriol])

Ointment calcitriol 3 micrograms/g; 100g

Calcipotriol

Ointment calcipotriol 50 micrograms/g; 30 g

Scalp solution calcipotriol 50 micrograms/mL; 60 mL

Calcipotriol with betamethasone (Dovobet)

Ointment calcipotriol 50 micrograms/g, betamethasone (as dipropionate) 0.05%; 60g, 120g

Gel calcipotriol 50 micrograms/mL, betamethasone (as dipropionate) 0.05%; 60g

Tacalcitol (Curatoderm)

Ointment tacalcitol 4 micrograms/g; 30g, 60g

Tazarotene (Zorac)

Gel 0.05%; 30g

0.1%; 30g

Tar

Coal Tar and Salicylic Acid

Ointment, BP 500 g

Carbo-Dome[®] cream 10%; 30g

Exorex[®] Lotion 1%; 250mL

Sebco[®] scalp ointment coal tar solution 12%, salicylic acid 2%, precipitated sulphur 4%, in a coconut emollient basis

Polytar Emollient[®]

Bath additive 350 mL

Dithranol

FOR IN-PATIENT USE ONLY

Dithranol Paste, BP Paste dithranol in zinc and salicylic acid (Lassar's)

Paste - a range of strengths available as extemporaneous items

Dithrocream[®] Cream 0.1%, 0.25%, 0.5%, 1%, 2%

Barnet and Chase Farm hospitals

Salicylic acid

Salicylic Acid Ointment, BP 450 g

Oral retinoids for psoriasis

Acitretin (Neotigason®)

Hospital only

Capsules 10 mg, 25 mg

13.5.3

Drugs affecting the immune response

Ciclosporin

Neoral capsules are available for use in transplant patients only.

See section 8.2.2

Methotrexate

See section 8.2.2

Pimecrolimus

Cream 1%; 30g

In line with NICE guidance TA82

Tacrolimus

Ointment 0.03%; 30g, 60g

0.1%; 30g, 60g

Cytokine modulators

Adalimumab

Injection 40mg

In line with NICE guidance TA146

Etanercept

Injection 25mg, 50mg

In line with NICE guidance TA103 & TA199

Infliximab

Injection 100mg

In line with NICE guidance TA199

Ustekinumab

Injections 45mg

In line with NICE guidance TA180

13.6

Acne and rosacea

13.6.1

Topical preparations for acne

Benzoyl peroxide

Gel 5%, 10%

Wash 10%

Duac® Once Daily Gel clindamycin 1%, benzoyl peroxide 5%; 25 g

Quinoderm® Cream 50g

Barnet and Chase Farm hospitals

Azelaic acid

Finacea [®] gel	azelaic acid 15%, 30g
Skinoren [®] cream	azelaic acid 20%, 30g

Topical antibacterials for acne

Antibacterials

Dalacin T[®]

Topical solution	clindamycin phosphate 1%; 30 mL (alcohol base)
Lotion	clindamycin phosphate 1%; 30 mL (non-alcoholic)

Stiemycin[®]

Topical solution	erythromycin 2% in alcoholic base; 50mL
------------------	---

Zineryt[®]

Topical solution	erythromycin 40 mg, zinc acetate 12 mg/mL; 30mL
------------------	---

Topical retinoids and related preparations for acne

Adapalene

Cream	0.1%; 45g
Gel	0.1%; 45g

Adapalene with benzoyl peroxide

Gel (Epiduo [®])	adapalene 0.1%, benzoyl peroxide 2.5%; 45g
<i>Cutaneous treatment of acne vulgaris when comedones, papules and pustules are present</i>	

Isotretinoin

Gel	0.05%; 30g
-----	------------

Isotretinoin with antibacterial

Gel	isotretinoin 0.05%, erythromycin 2%; 30g
-----	--

Tretinoin

Retin-A[®]

Gel	0.01%, 0.025%; 60 g
-----	---------------------

13.6.2

Oral preparations for acne

Hormone treatment for acne

Co-cyprindiol

Tablets	cyproterone acetate 2 mg, Ethinylestradiol 35 micrograms
---------	---

Barnet and Chase Farm hospitals

Oral retinoid for acne

Isotretinoin

(Hospital only)

Capsules 5 mg, 10mg, 20 mg

13.7

Preparations for warts and calluses

Salicylic acid

Occlusal[®] solution salicylic acid 26% in polyacryl solution 10mL

Salactol[®] Paint salicylic acid 16.7%, lactic acid 16.7%
In flexible colloidon; 10 mL

Silver nitrate

Pencil 75%, 95%

Anogenital warts

Imiquimod

Cream 5%

Imiquimod (for actinin keratosis and basal cell carcinoma)
Recommended according to local protocols, by North Central London JFC

Podophyllum

Podophyllum Paint,
Compound, BP 10 mL

Warticon[®]

Cream Podophyllotoxin 0.15%, 5g
Solution Podophyllotoxin 0.5% in alcohol base; 3 mL
(For penile warts)

13.8

Sunscreens and camouflages

13.8.1

Sunscreen preparations

Sunsense[®] Ultra 50+ Lotion SPF 50+
Uvistat[®] Sunblock cream SPF 20, SPF 50
Uvistat Ultrablock[®] cream SPF 30
Sun E45[®] SPF25+

Photodamage

Diclofenac sodium

Gel (**Solaraze**[®]) 3%; 25g

Methyl-5-aminolevulinate

Cream (**Metvix**[®]) 2g

For treatment of basal cell carcinoma and actinic keratosis in patients whom other therapy is not suitable

Barnet and Chase Farm hospitals

Fluorouracil

Cream (Efudix[®]) 5%, 40g

Ingenol mebutate (Picato) – non-formulary.
Rejected by North Central London JFC.

13.8.2

Camouflages

Products obtained as necessary

13.9

Shampoos and other preparations for scalp and hair conditions

Capasal[®] Shampoo	coal tar 1%, coconut oil 1%, salicylic acid 0.5% 500 mL
Nizoral[®] Shampoo	ketoconazole 2%
Polytar[®] Liquid	150 mL
Polytar Plus[®] Shampoo	500mL
Selsun[®] Shampoo	selenium sulphide 2.5%; 150 mL

Male pattern baldness

Regaine[®] Topical solution minoxidil 2% in alcoholic base; 60 mL

Available only on private prescription

13.10 Anti-infective skin preparations

13.10.1 Antibacterial preparations

13.10.1.1 Antibacterial preparations only used topically

Mupirocin (Bactroban[®])

Ointment mupirocin 2%; 15 g

Neomycin sulphate (Cicatrín[®])

Dusting powder neomycin sulphate 3300 units, bacitracin zinc
250 units, cysteine 2mg, glycine 10 mg,
threonine 1 mg/g; 15 g

Polymixins

Polyfax[®] ointment 20g

Silver sulfadiazine

Cream silver sulfadiazine 1%; 50 g, 250 g

13.10.1.2 Antibacterial preparations also used systemically

Fusidic acid

Cream 2%; 15 g

Ointment 2%; 15 g

Metronidazole

Gel (**Acea[®]**, **Metrosa[®]**) 0.75%; 40 g

Gel (**Anabact[®]**) 0.75%; 15g

Barnet and Chase Farm hospitals

13.10.2 Antifungal preparations

Amorolfine

Nail lacquer 5%; 5mL

Clotrimazole

Cream 1%; 20 g

Solution 1%; 20 mL

Ketoconazole

Cream 2%; 30 g

Shampoo see section 13.9

Miconazole nitrate

Cream 2%; 30 g

Nystatin

Cream (**Nystaform**[®]) nystatin 100 000 units, chlorhexidine 1%; 30g

Terbinafine

Cream 1%; 15 g

13.10.3 Antiviral preparations

Aciclovir

Cream 5%; 2g, 10g

13.10.4 Parasiticial preparations

Suitable quantities of parasiticial preparations

	Skin creams	Lotions	Cream rinses
Scalp (headlice)	----	50 mL	50-100 mL
Body (Scabies)	30-60 g	100 mL	----
Body (crab lice)	30-60 g	100 mL	-----

Benzyl Benzoate Application 25%; 500 mL

Malathion (**Derbac-M**[®]) Liquid 0.5% in aqueous base; 50 mL

Permethrin (**Lyclear**[®])

Cream 5%; 30 g

Crème Rinse 1%; 50 mL

13.10.5 Preparations for minor cuts and abrasions

Proflavine Cream, BPC 100 mL

Magnesium Sulphate Paste, BP 25 g

Colloidon, Flexible, BP 10 mL

Liquidband[®] 0.5g

Barnet and Chase Farm hospitals

13.11	Skin cleansers, antiseptics, and desloughing agents	
13.11.1	Alcohols and saline	
	Alcohol	
	Industrial Methylated Spirit, BP	70%; 500 mL
	Sodium chloride	
	Sterile spray	0.9%; 240mL
13.11.2	Chlorhexidine Salts	
	Chlorhexidine	
	Surgical scrub	4%; 500mL
	Obstetric cream	1%; 250mL
	Sachets (Unisept [®])	0.05%; 25mL, 100mL
	Chlorhexidine with cetrimide	
	Sachets (Tisept [®])	chlorhexidine 0.015%, cetrimide 0.15%; 25mL, 100mL
13.11.4	Iodine	
	Povidone-iodine	
	Alcoholic solution	10%; 500mL
	Antiseptic solution	10%; 500mL
	Surgical solution	7.5%; 500mL
	Dry powder spray	2.5%; 100mL
13.11.6	Oxidisers, and dyes	
	Hydrogen peroxide	
	Solution	10vol (3%); 200mL
	Potassium Permanganate	
	Solution tablets	400mg
13.12	Antiperspirants	
	Aluminium chloride hexahydrate	
	Application	20%; 60mL
	Glycopyrronium Bromide	
	Powder	3g
13.13	Topical circulatory products	
	Hirudoid [®] cream	heparinoid 0.3%

Chapter 14

Immunological products and vaccines

14 Immunological products and vaccines

14.4 Vaccines and antisera

BCG vaccine

BCG vial

Diagnostic agents

Tuberculin Purified Protein Derivative 20units/mL, 100units/mL
(Tuberculin PPD)

Diphtheria-containing vaccines

Diphtheria, tetanus, pertussis and polio prefilled syringe

Diphtheria, tetanus and inactivated polio prefilled syringe

Diphtheria, tetanus and acellular pertussis prefilled syringe

Diphtheria, tetanus, pertussis, polio and Hib 0.5mL vial

Diphtheria antitoxin ampoule

Haemophilus Type B conjugate vaccine

Menitorix[®] 0.5mL vial

Hepatitis A vaccine

Single component

Avaxim[®] 0.5 mL prefilled syringe

Vaqta[®] Paediatric 0.5 mL prefilled syringe

Havarix[®] ***Monodose*** 1mL prefilled syringe

Havarix[®] ***Monodose*** Paediatric 0.5mL prefilled syringe

Hepatitis B vaccine

Engerix B[®]

20 micrograms in 1 mL 1 mL prefilled syringe
0.5 mL (paed) prefilled syringe

HBvaxPRO[®]

10 micrograms in 1 mL 1 mL prefilled syringe
0.5 mL (paed) prefilled syringe

Influenza vaccine

0.5 mL prefilled syringe

Barnet and Chase Farm hospitals

Measles, Mumps and Rubella (MMR) vaccine

MMRvaxPro[®] single dose vial

Meningococcal vaccine

Meningococcal group C single dose vial

Meningococcal ogliosaccharide A, C, W135 and Y conjugate single dose vial

Meningococcal polysaccharide A, C, W135 and Y single dose vial

Pneumococcal vaccine

Pneumovax[®] II 0.5 mL vial

Prevenar 13[®] prefilled syringe

Rabies vaccine

1 mL ampoule

Typhoid vaccine

prefilled syringe

Varicella-Zoster vaccine

prefilled syringe

14.5 Immunoglobulins

For more information on immunoglobulin supply and demand:

<http://www.bcf.nhs.uk/intranet/pharmacy/ivig-demand-manage/index? ts=139556>

14.5.3 Disease-specific immunoglobulins

Tetanus

Injection 250 units

14.5.4 Anti-D (Rho) immunoglobulin

Injection 250 units, 1500 units

As 2nd line treatment for patients with ITP who have relapsed following steroid therapy.

Chapter 15
Anaesthesia

15	Anaesthesia	
15.1	General anaesthesia	
15.1.1	Intravenous anaesthetics	
	Barbiturates	
	<u>Thiopental sodium</u>	
	Injection	2.5% 500 mg vial
	Other intravenous anaesthetics	
	<u>Etomidate</u>	
	Injection	20 mg in 10 mL
	<u>Ketamine</u>	
	Injection	200 mg in 20 mL, 500 mg in 10 mL, 1000mg in 10mL
		<i>Preservative-free formulations are unlicensed, therefore named patient use only</i>
	<u>Propofol</u>	
	Injection (emulsion)	10mg in 1mL (pre-filled syringe), 200 mg in 20 mL, 500 mg in 50 mL, 1g in 50mL, 1 g in 100 mL
15.1.2	Inhalational anaesthetics	
	Volatile anaesthetics	
	<u>Desflurane</u>	
	Liquid	240 mL
	<u>Isoflurane</u>	
	Liquid	250 mL
	<u>Sevoflurane</u>	
	Liquid	250 mL
15.1.3	Antimuscarinic drugs	
	<u>Atropine sulphate</u>	
	Injection	600 micrograms in 1 mL, 1mg in 1mL
	Minijet	600 micrograms in 1 mL 1 mg in 10 mL, 3 mg in 10 mL, 3mg in 30mL
	<u>Glycopyrronium bromide</u>	
	Injection	200 micrograms in 1 mL 600 micrograms in 3 mL
	<u>Hyoscine hydrobromide</u>	
	Injection	400 micrograms in 1 mL, 600 micrograms in 1mL

Barnet and Chase Farm hospitals

15.1.4	Sedative and analgesic peri-operative drugs	
15.1.4.1	Benzodiazepines	
	<u>Diazepam</u>	
	See section 4.8.2	
	<u>Lorazepam</u>	
	See section 4.1.2	
	<u>Midazolam</u>	
	Injection	5mg in 5mL, 50 mg in 50 mL vial, 10 mg in 2mL, 10 mg in 5 mL
	<u>Temazepam</u>	
	See section 4.1.1	
15.1.4.2	Non-opioid analgesics	
	<u>Diclofenac sodium</u>	
	See section 10.1.1	
	<u>Ketorolac trometamol</u>	
	Injection	10 mg in 1 mL, 30mg in 1 mL
15.1.4.3	Opioid analgesics	
	<u>Alfentanil</u>	
	Injection	1 mg in 2 mL, 5mg in 1mL, 5mg in 10mL
	<u>Fentanyl</u>	
	Injection	100 micrograms in 2mL, 500 micrograms in 10 mL
	<u>Remifentanil</u>	
	Injection	1mg, 2mg, 5mg
15.1.5	Neuromuscular blocking drugs	
	Non-depolarising muscle relaxants	
	<u>Atracurium besilate</u>	
	Injection	25 mg in 2.5 mL, 50 mg in 5 mL, 250 mg in 25 mL
	<u>Mivacurium</u>	
	Injection	10 mg in 5 mL, 20 mg in 10 mL
	<u>Pancuronium bromide</u>	
	Injection	4 mg in 2 mL
	<u>Rocuronium bromide</u>	
	Injection	50 mg in 5mL
	<u>Vecuronium bromide</u>	
	Injection	10 mg vial

Barnet and Chase Farm hospitals

Depolarising muscle relaxants

Suxamethonium chloride

Injection	100 mg in 2 mL
Minijet	100 mg in 2mL

15.1.6 Drugs used for reversal of neuromuscular blockade

Neostigmine metisulfate

Injection	2.5 mg in 1 mL
-----------	----------------

Neostigmine metisulfate / Glycopyrronium bromide

Injection	2.5 mg / 500 micrograms in 1 mL
-----------	---------------------------------

Sugammadex

Injection	500 mg in 5 mL
-----------	----------------

Sugammadex (for emergency reversal of rocuronium)
Recommended for infrequent emergency use only , by North Central London JFC
Restricted to obstetric use only

15.1.7 Antagonists for central and respiratory depression

Doxapram hydrochloride

See section 3.5.1

Flumazenil

Injection	500 micrograms in 5 mL
-----------	------------------------

(Caution: Flumazenil has a short half-life compared to other benzodiazepines. In theatre, to be used only on request of Consultant)

Naloxone hydrochloride

Injection	400 micrograms in 1 mL
Minijet	2mg/5mL, 400micrograms/1mL

15.1.8 Drugs for malignant hyperthermia

Dantrolene sodium

Injection	20 mg
-----------	-------

Barnet and Chase Farm hospitals

15.2

Local anaesthesia

Lidocaine (Lignocaine)

Lidocaine hydrochloride / Lignocaine hydrochloride

Injection	0.5%	10 mL amp
	1%	2 mL amp
	1%	5 mL amp
	1%	10 mL amp
	1%	20 mL amp
	2%	2 mL amp
	2%	5 mL amp
	2%	20 mL amp
Minijet	2%	
Ointment	5%	15 g
Spray	10%	
Solution (Laryngojet [®])	4%	

Lignocaine with Adrenaline 1 in 80, 000

Injection	2%
-----------	----

Lignocaine with Adrenaline 1 in 100, 000

Injection	4% cartridge
-----------	--------------

Lignocaine with Adrenaline 1 in 200, 000

Injection	1%	20 mL vial
	2%	20 mL vial

Lignocaine 2.5% with Prilocaine 2.5%

Cream (Emla [®])	5 g
----------------------------	-----

Lignocaine 2% with Chlorhexidine gluconate solution 0.25%

Gel (Instillagel [®])	11mL
---------------------------------	------

Lignocaine 5% with Phenylephrine 0.5%

Solution for nasal use	2.5mL
------------------------	-------

Lidocaine, adrenaline and tetracaine (LAT)

Gel	Lidocaine 4%, adrenaline 0.1%, tetracaine 0.5%
-----	--

For local anaesthetics in children and needle phobic adults. Unlicensed use, so prescribing doctor to complete documentation for legislation purposes

Lidocaine plasters (Verstis) – non-formulary.
Rejected by North Central London JFC.

Barnet and Chase Farm hospitals

Bupivacaine

Bupivacaine hydrochloride

Injection 0.25% 10 mL amp
0.50% 10 mL amp

Bupivacaine hydrochloride 5 mg with Glucose 80 mg per mL
Injection 20 mg / 320 mL per 4 mL

Bupivacaine hydrochloride 0.1% with Fentanyl 2 micrograms per mL
Epidural infusion bag 100 mL, 250 mL

Bupivacaine hydrochloride 0.125% with Fentanyl 4 micrograms per mL
Epidural infusion bag 500mL (not in BNF)

Bupivacaine hydrochloride with Adrenaline 1 in 200 000
Injection 0.25% 10 mL amp
0.50% 10 mL amp

Levobupivacaine Hydrochloride

Injection 2.5 mg in 1 mL, 5 mg in 1 mL, 7.5mg in 1mL

Levobupivacaine 0.1% with Fentanyl 2 micrograms per mL
Epidural infusion bag 100 mL, 250 mL

Levobupivacaine 0.125% with Fentanyl 4 micrograms per mL
Epidural infusion bag 500mL

Prilocaine hydrochloride

Injection 1% 50mL
Injection (hyperbaric) 2% 10mL

Prilocaine hyperbaric for spinal anaesthesia
Under 1 year evaluation at BCF day surgery unit only (North Central London JFC)

Prilocaine hydrochloride with Felypressin

Injection 60 mg / 0.06 unit in 2 mL cartridge

Ropivacaine Hydrochloride

Injection 20 mg in 10 mL, 75 mg in 10 mL, 100mg in 10mL
Infusion 400mg in 200mL

Tetracaine/Amethocaine

Gel (Ametop[®]) 1.5g

Ethyl Chloride

Spray

Emergency treatment of Poisoning

Methaoglobinaemia

Methylthioninium chloride (Proveblue®)

Injection 1 %

Removal and elimination

Charcoal activated

Oral suspension

Charcoal activated (Carbomix®)

Granules

Specific drugs

Paracetamol poisoning

Acetylcysteine

Injection 200 mg in 1ml

Prevention of renal toxicity is unlicensed – this indication is on a Named Patient basis only

Methionine

Tablets 500 mg

Analgesics (opioid)

Naloxone

Injection 400 micrograms in 1ml

Min-i-jet 2 mg in 5ml

Min-i-jet 400 micrograms in 1ml

Iron Salts – see Desferrioxamine section 9.1.3

Cyanides

Dicobalt edetate

Injection 300 mg

Sodium nitrite

Injection 3 %

Sodium thiosulphate

Injection 50 % w/v (10ml)

Pesticides

Pralidoxime chloride

Injection 1 g

Barnet and Chase Farm hospitals

Miscellaneous preparations

Diagnostic aids and contrast media

Gadolineum (Primovist®)

Pre-filled syringe 10mL

For detection of liver metastases particularly in colorectal malignancy patients, HCC, FNH and adenoma

Hexaminolevulinate

Kit (Hexvix®)

To be used in the detection of bladder cancer (to replace the use of unlicensed 5-ALA)

Regadenoson

Injection 400 micrograms

Regadenoson (for perfusion imaging)
Recommended for perfusion imaging in patients for whom exercise stress testing is to be avoided, by North Central London JFC

Other pharmacy preparations

Fibrin sealant

Kit (Evicel®) 2mL, 5mL

Kit (Tiseel Lyo®) 2mL

Tiseel (for conjunctival surgery)
Recommended in preference to sutures for pterygium surgery, by North Central London JFC

Probiotic nutritional supplement (VSL#3®)

Sachet 4.4g

For use in patients with pouchitis ONLY

VSL#3 (for pouchitis)
Recommended for patients with Pouchitis only, by North Central London JFC

Chlor-Clean®

Tablets

For terminal cleaning. For other environmental cleaning use Haz-Tabs®